

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER REDC-710 USA	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/530298	
INTERNATIONAL APPLICATION NO. PCT/US98/23705		INTERNATIONAL FILING DATE 06 November 1998 (06.11.98)		PRIORITY DATE CLAIMED 07 November 1997 (07.11.97)	
TITLE OF INVENTION AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN					
529 Rec'd PCT/PTO 27 APR 2000					
APPLICANT(S) FOR DO/EO/US KRANTZ, Alexander; HUANG, Wolin; HANEL, Arthur M.; HOLMES, Darren L.; and BRIDON, Dominique P.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). (unsigned) 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none"> 13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. w/Form 1449 and cited prior art refs. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 20. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> a. Twenty sheets of formal drawings, comprising Figures 1 through 20, inclusive. b. Copy of Preliminary Amendment and replacement pages 2, 3, 4, 50, 51, and 59 filed 16 March 1999 (16.03.99). c. Copy of International Application No. PCT/US98/23705 as published under International Publication Number WO 99/24075 on 20 May 1999 (20.05.99) (without International Search Report). d. Copy of International Application No. PCT/US98/23705 republished (front page only) with International Search Report on 02 September 1999 (02.09.99). e. Copy of Form PCT/IPEA/402 - Notification of Receipt of Demand by Competent International Preliminary Examining Authority. f. Copies of Forms PCT/IB/301, PCT/IB/304, PCT/IB/306, PCT/IB/308, and PCT/IB/332. g. Verified Statement Claiming Small Entity Status - Small Business Concern (signed). 					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/530298	INTERNATIONAL APPLICATION NO. PCT/US98/23705	ATTORNEY'S DOCKET NUMBER REDC-710 USA
--	--	---

21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$840.00	
				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	57 - 20 =	37	x \$18.00	\$666.00	
Independent claims	3 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,506.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				\$753.00	
SUBTOTAL =				\$753.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
TOTAL NATIONAL FEE =				\$753.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$753.00	
				Amount to be refunded	\$
				charged	\$

- ☒ A check in the amount of **\$753.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1420** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael R. Ward, Esq.
 LIMBACH & LIMBACH L.L.P.
 2001 Ferry Building
 San Francisco, California 94111-4207
 United States of America
 Telephone: (415) 433-4150
 Facsimile: (415) 433-8716

Michael R. Ward
 SIGNATURE

MICHAEL R. WARD
 NAME

38,651
 REGISTRATION NUMBER

26 April 2000 (26.04.00) *new*
 DATE

Applicant or Patentee: ALEXANDER KRANTZ ET AL.
 Appln. or Patent No.:
 Filed or Issued: HEREWITH
 For: AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

Attorney's Docket No. RDC-710 USA

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN CONJUCHEM, INC.

ADDRESS OF CONCERN 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8, Canada

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN by inventor(s) ALEXANDER KRANTZ ET AL. described in

- ☒ the specification filed herewith with title as listed above.
☐ application no. _____, filed _____
☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME _____

ADDRESS _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

NAME _____

ADDRESS _____
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time or paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dominique P. Bridon

TITLE OF PERSON OTHER THAN OWNER Vice President of Research

ADDRESS OF PERSON SIGNING 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8, Canada

SIGNATURE _____

DATE: Apr 13, 2000

09/530298

422 Rec'd PCT/PTO 2 7 APR 2000

PATENT COÖPERATION TREATY

UNITED STATES RECEIVING OFFICE

In re Int'l Application of) Paralegal Specialist:
CONJUCHEM, INC. ET AL.) Theodosia Simpkins
)
International Application) PRELIMINARY AMENDMENT
No. PCT/US98/23705) AND REPLACEMENT PAGES
) FOR SPECIFICATION OF
International Filing Date:) <u>INTERNATIONAL APPLN.</u>
06 November 1998 (06.11.98))
)
For: AFFINITY MARKERS FOR) 2001 Ferry Building
HUMAN SERUM ALBUMIN) San Francisco, CA
) 94111-4262
) (415) 433-4150

Assistant Commissioner for Patents
 Box PCT
 Washington, D. C. 20231-0001

Attention: RO/US

CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this Preliminary Amendment and attached Replacement Pages for the specification of the above-identified International Application are being deposited with the United States Postal Service on this date **March 16, 1999**, in an envelope bearing "Express Mail Post Office To Addressee" Mailing Label Number **EM393842640US** addressed to: Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231-0001, Attention: RO/US.

Elizabeth A. Reicker
 Name

Elizabeth A. Reicker
 Signature

Sir:

This is a preliminary amendment to conform the specification with the revised formal drawings submitted with the Response to Invitation to Correct Defects in the above-identified International Application. The amendment to the specification is to reflect the splitting of original Figure 15 into new Figures 15A and 15B. In addition, the amendment deletes superfluous ellipses on

original pages 2, 3, and 59, and completes the sentence on original page 2, line 25. Replacement pages 2, 3, 4, 50, 51, and 59 are enclosed herewith. The specification has been amended as follows:

IN THE SPECIFICATION

In page 2, line 25, "?????" has been replaced by -- (for "long chain") has the formula $\text{-NH-(CH}_2\text{)}_n\text{-C(O)-}$, where n is an integer between 1 and 25.--.

In page 2, line 28, "....." has been deleted.

In page 3, line 4, "....." has been deleted.

In page 4, line 20, "Figure 15 shows" has been replaced by --Figures 15A and 15B show--.

In page 50, line 20, "Figure 15 shows" has been replaced by --Figures 15A and 15B show--.

In page 51, line 3, "(Figure 15) has been replaced by --(Figures 15A and 15B)--.

In page 51, line 7, "(Figure 15," has been replaced by --(Figures 15A and 15B,--.


In page 51, line 22, "(Figure 15)" has been replaced by --(Figures 15A and 15B)--.

In page 59, line 26, "....." has been deleted.

Respectfully submitted,

LIMBACH & LIMBACH L.L.P.

Dated: March 16, 1999

By: 
Patricia Coleman James
Registration No. 37,155
2001 Ferry Building
San Francisco, CA 94111
(415) 433-4150
Attorneys for Applicants

PCJ/EAR
REDC-710 PCT

20 / P P E T

422 HECG PCT/PTU 2 / APR 2000

AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

RELATED APPLICATIONS

This application is a non-provisional application, claiming benefit under 35 U.S.C. § 119(e) of United States Provisional Application No. 60/06470~~5~~, entitled BIOCONJUGATION AND AFFINITY GROUPS filed November 7, 1997 and United States Provisional Application No. 60/077927 entitled F/YEE AFFINITY MARKER filed March 13, 1998.

FIELD OF THE INVENTION

This invention relates to libraries of affinity markers, and especially F/YEE, for human serum albumin. This invention is further related to methods of screening the affinity marker libraries, identification of specific markers and the use of the markers as delivery agents for therapeutic *in vitro* and *in vivo* diagnostic agents.

BACKGROUND OF THE INVENTION

The advent of combinatorial chemistry has provided a platform for a wide variety of opportunities. The ability to produce large libraries of different compounds means that one can screen a large array of conformations, and charge distributions for their ability to bind to other compounds to act as agonists or antagonists, in binding to specific sites of a target protein, to investigate the conformation of a particular protein site, such as an enzymatic cleft or membrane channel protein, and the like.

The existence of combinatorial chemistry affords new opportunities towards new therapies for diseases for which prior drugs are inadequate or for which there are no present successful therapies. The presently available drugs are inadequate for a wide variety of reasons, in many cases, the pharmacokinetics of the drugs. Parenteral delivery in a bolus has many constraints on its efficacy. Since most drugs have serious side effects, one is constrained as to the upper dosage level. On the other hand, drugs may undergo enzymatic modification, oxidation, degradation in the liver, secretion, and the like, so that the lifetime of the drug will be limited by the various mechanisms which serve to diminish the effective level of the drug.

Drugs which have been approved for use with humans have already been shown to be generally safe at the prescribed dosage and effective. Therefore, there are substantial advantages in being able to modify these drugs, where their safety and efficacy are not unduly altered. In this way, the economies of dealing with known entities can be achieved, while at the same time increasing the available therapeutic opportunities.

BRIEF SUMMARY OF THE INVENTION

The present invention addresses these and other problems of the prior art by providing compounds having the formula $E-C_a-R-C_b-A$. In this formula, E contains an active diagnostic moiety or pharmacophore and suitable connectors, R is a potentially reactive functional group contained within the entity and is capable of transferring an active diagnostic moiety or pharmacophore. C_a and C_b are connector groups between E and R and between R and A, respectively. A is any molecule or part of a molecule that possess specific binding determinants for a target molecule, such as proteins including human serum albumin. (These components of compounds according to the present invention are defined more fully below.) In some compounds according to the invention, affinity group A comprises a sequence of amino acid residues $-O_1-O_2-X_1-X_2-B$ in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. A particularly preferred sequence is F/YEE. Preferred compounds according to the invention include biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-OPh-C(O)-F/YEE-NH₂, LC-biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-Gly-OPh-C(O)-F/YEE-NH₂, fluorescein-Gly-OPh-F/YEE-NH₂, LC-biotin-OPh-C(O)-F/YEE-NH₂, argatroban-AEA₃-βAla-Gly-OPh-C(O)-F/YEE-NH₂ and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-F/YEE-NH₂, where LC is ????? These compounds can bind to specific proteins in vivo and enhance the half lives of diagnostic and therapeutic agents as well as control side effects.

.....The present invention is also directed to methods for screening for the affinity of a compound for active sites on a target molecule. In methods according to the invention, the target molecule is immobilized on a test substrate and then incubated with the compound under conditions that support interaction (i.e., noncovalent

binding) between the compound and the active sites on the target molecule. Then, the interaction between the active sites and the compound is quenched. Thereafter, an assay can be performed to detect the activity of the target molecule.

.....This invention could be seen as a replacement for some antibody uses, particularly in the field of in vitro diagnostic or in vivo therapy. The present invention is an improvement on US Patent 5 612 034 (Pouletty, et al.) teaching the art of labeling protein in vivo in a nonspecific manner since the present invention extends the life of the drug and controls its distribution, thereby limiting its side effects.

BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be better understood by reference to the figures, in which:

Figure 1 shows the structural formula of the most preferred affinity group of the invention, -F/YEE.

Figure 2 shows a reaction scheme for the use of a preferred embodiment of the invention for covalently attaching biotin to HSA.

Figure 3 shows a schematic illustration of the construction of an affinity labeling library of the present invention.

Figure 4 shows optical density measurement for the screening of a library according to the present invention at the level of 81 compounds per well with a 1 minute quenching time

Figure 5 shows optical density measurement for the screening of a library according to the present invention at the level of 81 compounds per well with a 15 minutes quenching.

Figures 6a and 6b show optical density measurements for the screening of a library according to the present invention at the level of 9 compounds per well.

Figure 7 shows an immunoblot in which human serum and plasma samples were labeled with two different concentrations of biotin-OPh-CO- NH₂ to assess compound lack of specificity in the absence of F/YEE peptide.

Figure 8 shows a plot of optical density as a function of HO-Ph-CO- F/YEE-NH₂ concentration in an experiment to investigate competitive binding to HSA.

Figure 9 shows a plot of optical density as a function of HO-Ph-CO- F/YEE - NH₂ concentration in an experiment to investigate competitive binding to HSA as compared to biotin-Oph-CO-F/YEE- N⁺.₂.

Figure 10 shows a plot of optical density as a function of time for a kinetic study by ELISA capture in which human plasma was treated with biotin-Oph-CO-F/YEE- NH₂, biotin-Oph-CO- NH₂, NHS-LC-biotin or biotin-BMCC (BMCC is 1-biotinamido-4-[4'-(maleimidomethyl)cyclohexanecarboxamido]butane).

Figure 11 shows a graph showing the rate of disappearance of biotin-Oph-CO- NH₂ and appearance of HO-Ph-CO- NH₂ as a result of reaction of HSA with biotin-Oph-CO- NH₂.

Figure 12 shows a plot of the concentration of HO-Ph-CO-F/YEE -NH₂ resulting from the reaction of biotin-Oph-F/YEE-NH₂ in commercial human plasma as a function of time.

Figure 13 shows a plot of the concentration of HO-Ph-CO- F/YEE -NH₂ and biotin-Oph-CO-F/YEE -NH₂ as a function of time during hydrolysis of biotin-Oph-CO-F/YEE- NH₂ in PBS (pH 7.4, RT).

Figure 14 shows a plot of the concentration of HO-Ph-CO- F/YEE -NH₂ as a function of time during reaction of biotin-Oph-CO- F/YEE- NH₂ with HSA in PBS (pH 7.4, RT).

Figure 15 shows HPLC chromatographs of tryptic digest of HSA (top) and HSA:LC-biotin (bottom).

Figure 16 is a reaction scheme setting forth the procedure for the synthesis of biotin-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 17 is a reaction scheme setting forth the procedure for the synthesis of biotin-Gly-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 18 is a reaction scheme setting forth the procedure for the synthesis of LC-biotin-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 19 is a reaction scheme setting forth the procedure for the synthesis of argatroban-AEA₃-βAla-Gly-Oph-CO-F/YEE-NH₂ •2 TFA according to the invention.

Figure 20 is a reaction scheme setting forth the procedure for the synthesis of Fluorescein-thiourea-AEA-Gly-Oph-CO-F/YEE-NH₂ according to the invention.

DETAILED DESCRIPTION OF THE INVENTION

In order to ensure a complete understanding of the invention, we first provide definitions of terms used in this patent. We then discuss the results of specific screening experiments used to determine affinity groups for labeling human serum albumin (HSA). We discuss the specific affinity groups identified by the screening and the specific entity, reactive groups, and connecting groups used in the library screening experiments. We then discuss more general target molecules, affinity groups, reactive groups, connecting groups and entities that fall within the scope of the invention. Finally, we present experimental results for the synthesis of the libraries used in the present invention together with the experimental screening results and the results of experiments characterizing the entity/target-molecule binding.

Definitions

Entity: a segment of an affinity labeling reagent that is to be covalently attached to the target molecule. Generally, the entity includes an active diagnostic moiety or pharmacophore and suitable connectors. Examples of possible diagnostic or therapeutic agents are provided below.

Affinity Group: any molecule or part of a molecule that possesses specific binding determinants for a target molecule. In the context of this filing, the affinity group includes oligomeric moieties such as peptides, carbohydrates and nucleotides and combinations thereof that confer affinity to the target molecule by virtue of their complementarity for specific sites of the target. Such oligomeric units distinguish affinity groups from connectors and reactive groups, all of which are components of the entity in rate. Since the activities of affinity reagents are measured in terms of the rate by which they covalently label their targets, any increase in rate above 100% (factor of 2) conferred by such oligomeric units, relative to a standard molecule lacking such oligomeric units, relative to a standard molecule lacking an oligomeric group complementary to the target, defines these groups as affinity groups in this

application. According to the invention, suitable affinity groups for labeling human serum albumin include oligomeric molecules including peptides, carbohydrates and nucleotides and combinations thereof.

5 **Reactive Group:** generally a potentially reactive organic functional group contained within the entity capable of transferring an active diagnostic moiety or pharmacophore. Reactive groups according to the invention may be bonded to the affinity group by a first connecting group. The reactive group may be bonded to the entity by a second connecting group and in this case, the bond between the reactive
10 group and the second connecting group must be able to cleave allowing the second connecting group to bond to the target molecule.

15 **Reactive Functional Group:** generally any group that may be incorporated in the molecules of the invention either between the reactive group and the affinity group or between the reactive group and the entity.

20 **Target Molecules:** any molecules to which affinity groups are complementary by virtue of specific binding determinants and to which the whole entity may react to form a covalent bond. Human serum albumin is the most preferred target molecule; examples of other preferred target molecules are discussed below.

In Vitro Diagnostic Agent: any molecule that finds use in *in vitro* diagnostic analysis.

25 **In Vivo Diagnostic Agent:** any molecule that finds use in *in vivo* diagnostic analysis.

Diagnostic Agents: Diagnostic agents include agents used in diagnostic techniques such as positron emission tomography (PET), computerized tomography (CT), single photon emission computerized tomography (SPECT), magnetic resonance imaging (MRI), nuclear magnetic imaging (NMI), fluoroscopy and ultrasound, fluorophors,
30 chromophors and chemiluminophors.

Diagnostic agents of interest include contrast agents, radioisotopes of such elements as iodine (I), including ^{123}I , ^{125}I , ^{131}I , etc., barium (Ba), gadolinium (Gd), technetium (Tc), including ^{99}Tc , phosphorus (P), including ^{31}P , iron (Fe), manganese (Mn), thallium (Tl), chromium (Cr), including ^{51}Cr , carbon (C), including ^{11}C , or the like, fluorescently labeled compounds, and fluorine containing chemicals useful in ultrasound, etc.

Therapeutic Agent: any molecule that has a therapeutic (i.e., healing or curative) effect. Therapeutic agents are agents that have a therapeutic effect. Therapeutic agents include drugs, antibiotics, anti-infectives, anti-cancer agents, pain management agents, cardiovascular drugs (antithrombotics, anticoagulants, anti-platelet, protease inhibitors, calcium channel blockers, etc.), anti-inflammatory agents, antiproliferative drugs, oligonucleotides (sense and antisense). Therapeutic agents are generally drugs or small molecules having a molecular weight less than 2000.

Specific Affinity Groups for Human Serum Albumin

Using library screening techniques according to the invention and exemplified below, the inventors have identified a series of compounds that are useful for attaching an entity (usually a diagnostic or therapeutic agent) to human serum albumin (HSA).

In one embodiment of the present invention, the compounds have the formula, $\text{E-C}_a\text{-R-C}_b\text{-A}$, where E is the entity to be attached to the target molecule, C_a and C_b are connecting groups, R is a reactive group and A is an affinity group. C_b and C_a are also referred to herein as the first connecting group and the second connecting group, respectively. As discussed below, the connecting groups C_a and C_b may not be required and the invention also covers compounds of the formula $\text{E-R-C}_b\text{-A}$, $\text{E-C}_a\text{-R-A}$ and E-R-A .

As exemplified below, the inventors synthesized an affinity labeling library of general formula $\text{E-R-O}_1\text{-O}_2\text{-X}_1\text{-X}_2\text{-B-NH}_2$ and screened this library of compounds against HSA as the target molecule. For the diagnostic screening, E was a biotin group; R was selected from $-\text{S-Ph-C(O)-}$ (example 1 below), $-\text{O-Ph-C(O)-}$ (example

2) and $-N-Ph-C(O)-$ (example 3); and O_1 , O_2 , X_1 , X_2 and B are amino acid residues selected from glutamic acid, glutamine, arginine, methionine, serine, tyrosine, leucine, phenylalanine and tryptophan. The inventors also synthesized an embodiment of the invention of the formula $E-C_a-R-O_1-O_2-X_1-X_2-B-NH_2$ where E is biotin and C_a is $-NH-(CH_2)_5-C(O)-$.

The library screening results indicated that library members exhibiting enhanced binding to HSA included the following amino acid residues:

O_1 is selected from phenylalanine, arginine, glutamine, tyrosine, glutamic acid and tryptophan;

O_2 is selected from leucine, arginine, glutamic acid, tryptophan and phenylalanine;

X_1 is selected from phenylalanine, tryptophan, methionine and tyrosine;

X_2 is selected from serine, arginine and glutamic acid; and

B is selected from serine, arginine and glutamic acid.

Analysis of these results suggest that hydrophobic residues are preferred at both the O_1 and O_2 positions, with large hydrophobic residues being more preferred; hydrophobic residues are also preferred at the X_1 position. Although the results do not appear to demonstrate any clear preference for different residues at the X_2 and B positions, based on other considerations discussed below, it appears that more polar, charged amino acids are preferable.

To reduce the possibility of degradation of a peptide affinity group (i.e., where two or more of the residues in $O_1-O_2-X_1-X_2-B$ are amino acids), one or more D-amino acid residues can be included in an L-amino acid peptide or one or more L-amino acid residues can be included in a D-amino acid peptide. For example, including a D-amino acid residue at position O_2 , X_1 , or X_2 in an L-amino acid peptide (or vice versa) will yield two D-L bonds, which may reduce degradation. In a preferred embodiment of this invention, the inventors included a D-amino acid residue at the O_2 position and included L-amino acid residues at the other positions.

Preferred combinations of the O_1 and O_2 residues are as follows:

O_1 is phenylalanine and O_2 is D-leucine;

O_1 is arginine and O_2 is D-arginine;

O₁ is glutamine and O₂ is D-glutamic acid;
O₁ is glutamic acid and O₂ is D-tryptophan;
O₁ is tryptophan and O₂ is D-tryptophan; and
O₁ is tryptophan and O₂ is D-glutamic acid.

5 In the most preferred combination, O₁ is phenylalanine and O₂ is leucine as determined by the analysis of Figure 4. Figure 4 represents the rate of addition, expressed as optical density units, of library members on HSA. An elevated value for the optical density is representative of a larger amount of biotin on HSA at a given time. A larger amount of biotin on HSA at a given time is representative of a higher
10 specificity of a library member or members for a given site, resulting in an accelerated addition of biotin on the target site.

The preferred amino acids at the X₁, X₂, and B positions are tyrosine, glutamic acid and glutamic acid respectively. The most preferred affinity group is -F/YEE, where F is phenylalanine, I is D-leucine, Y is tyrosine, and E is glutamic acid.

15 In a preferred embodiment, the B position amino acid residue is the C-terminal amino acid. In another preferred embodiment, the B position amino acid residue exists in its carboxamide form rather than in the carboxylic acid form. In this preferred embodiment the -F/YEE affinity group has the structural formula shown in Figure 1.

20 The screening experiments described herein identified the affinity groups discussed above and these screening results indicate that the affinity groups may preferentially bind to HSA and may therefore be useful in directing specific entities to covalently bind to HSA. Specific experiments demonstrating such specific binding are described in the EXPERIMENTS section.

25 **Reactive Groups (R)**

A preferred affinity marker compound of the present invention includes a reactive group (R) in addition to the affinity group described above. The reactive group may be connected through to the affinity group via a first connecting group (C₁)
30 or, preferably, is bonded directly to the affinity group.

Generally the reactive group, R, will include a reactive functional group selected from carboxy, phosphoryl, alkyl esters, thioesters, phosphoesters, ortho esters, imidates, mixed anhydrides, disulphides, amides and thioamines. It is preferred that the reactive group is stable in an aqueous environment. In a preferred embodiment, the reactive group will include an aromatic moiety, preferably a substituted or unsubstituted phenyl group.

Generally, the bond between the reactive group and the affinity group should be a thermodynamically stable, but potentially reactive covalent bond (i.e., irreversible bond). In a preferred embodiment of the invention, the reactive group is bonded directly to the O₁ amino acid of the affinity group. In a more preferred embodiment, the reactive group is bonded to the O₁ amino acid of the affinity group by an amide linkage.

In one embodiment of the invention, the reactive group has the formula $-X-R_1-C(O)-$, where X is sulfur, oxygen, or nitrogen; R₁ includes a substituted or unsubstituted aromatic group; and C(O) represents a carboxyl group. Also suitable is a reactive group of the formula $-X-R_1-C(S)-$, where X is sulfur, oxygen, or nitrogen; R₁ includes a substituted or unsubstituted aromatic group; and C(S) is a thiocarbonyl group. Preferably, X is sulfur or oxygen. In another preferred embodiment, X is directly bonded to an aromatic carbon in the R₁ group. In a more preferred embodiment, R₁ is a substituted or, preferably, an unsubstituted phenyl. In this context, by "substituted phenyl", we mean a phenyl group bearing substituents in addition to the $-X-$ and $-C(O)-$ groups explicitly laid out in the formula. In a more preferred embodiment, R₁ is unsubstituted phenyl and the $-X-$ and $-C(O)-$ substituents are bonded to the phenyl group in a para configuration. In another preferred embodiment of the invention, the reactive group carboxyl group is directly bonded to the O₁ amino acid of the affinity group, generating a stable amide bond.

In another embodiment of the invention, the reactive group is attached to the affinity group via a first connecting group. In this embodiment, suitable connecting groups may be as described below in the "General Connecting Groups" section.

Entity (E)

The reactive group may either be bonded directly to the entity or connected thereto via a second connecting group (C_a). The entity may generally be any fragment or moiety that is desired to be covalently bonded to the target molecule and preferred entities include a variety of pharmacophore and active diagnostic agents that are described in detail in the "General Entities" section below. In a preferred embodiment, the entity includes a biotin group.

When compounds according to the invention covalently react with to the target molecule, the covalent bond between the entity and the reactive group cleaves, liberating an -RL-A or -RL- C_b -A fragment, wherein RL is R after reaction with a nucleophile, whereby an entity/target-molecule covalent bond forms to attach the entity to the target molecule. This mechanistic understanding of the chemistry is useful in determining which entity/reactive-group bonds are most suitable. In a preferred embodiment of the invention, the entity is bonded to the reactive group by an amide, or more preferably, an ester or thioester bond.

In a preferred embodiment of the invention, the entity forms a covalent bond to an amino group on the target molecule and in this case an ester or thioester bond between the entity and the reactive group is preferred. However, in other embodiments of the invention, the entity can form covalent bonds to hydroxyl, thiol, or other available functional groups on the target molecule.

If the entity is to form a covalent bond with a hydroxyl group on the target molecule, it is preferred that the entity bonds to the reactive group by an ester bond. If the entity is to form a covalent bond with a thiol group on the target molecule, it is preferred that the entity is bonded to the reactive group by a thioester or disulfide bond.

Second Connecting Group (C_a)

Typical connecting groups that may be used are described in detail in the "General Connecting Groups" section below. In a preferred embodiment, the second connecting group LC (for "long chain") has the formula $-NH-(CH_2)_n-C(O)-$, where n is an integer between 1 and 25. In a more preferred embodiment, the second

connecting group has the formula $\text{-NH-(CH}_2\text{)}_5\text{-C(O)-}$ and $\text{-NH-CH}_2\text{-C(O)-}$. When a second connecting group is present, the mechanism for bonding the entity to the target molecule includes the breaking of the bond between the second connecting group and the reactive group and the formation of a bond between the second connecting group and a functional group on the target molecule. In this case, the entity will be attached to the target molecule via the second connecting group. One effect of the presence of the second connecting group is that the entity may be held sterically clear of the target molecule after it has been covalently attached; that is, the entity ends up tethered to the target molecule via the second connecting group. This aspect of the invention may be important in maintaining the activity of a therapeutic agent that may lose activity if it is too closely attached to the target molecule.

Preferred Embodiments

The following compounds are preferred embodiments of the present invention:

A compound selected from the group consisting of biotin-S-Ph-C(O)-FIYEE- NH_2 , biotin-OPh-C(O)-FIYEE- NH_2 , LC-biotin-S-Ph-C(O)-FIYEE- NH_2 , biotin-Gly-OPh-C(O)-FIYEE- NH_2 , fluorescein-Gly-OPh-FIYEE- NH_2 , LC-biotin-OPh-C(O)-FIYEE- NH_2 , argatroban-AEA₃- β Ala-Gly-OPh-C(O)-FIYEE- NH_2 , and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-FIYEE- NH_2 .

Use of Preferred Embodiments to Attach the Entity to HSA

Figure 2 shows the reaction scheme for the use of a preferred embodiment of the present invention **5** to attach a biotin group **10** (the entity) to HSA **40** (the target molecule). In the preferred embodiment shown in Figure 2, the reactive group **20** is an -O-Ph-C(O)- group and the affinity group **30** is -FIYEE. The entire molecule composed of **5**, **10**, **60**, **20** and **30** is referred to here as an affinity labeling reagent or drug affinity label conjugate. To form the target-molecule/entity complex **50**, the entity/reactive functional group bond **60** cleaves and an amine group **70** on the target molecule **40** forms an amide bond **80** via a B_{AC}2 mechanism with the entity **10**. The reactive-group/affinity-group molecule **90** is liberated. The specific experimental

Affinity groups exhibit an affinity through non-covalent binding and association with biologically active molecules. Generally, the affinity groups represented in any particular library will be of a common type. Oligomeric affinity groups will be characterized by their ready synthesis as a combinatorial library, so that the synthetic chemistry is substantially repetitive with the addition of each monomer unit to the growing oligomer. Also, methods will be available for analyzing the composition and/or sequence of the oligomeric affinity group.

Alternatively, the affinity group may comprise small synthetic organic molecules having a molecular weight of at least about 200, and not more than about 5,000, generally ranging from about 250 to 2,000.

Generally, the oligomers employed will have at least 3 monomeric units and usually fewer than 20 monomeric units. The oligomers usually have at least 4, but fewer than 12 monomeric units and more preferably fewer than 10 monomeric units. Most preferably, the oligomers have between 4 to 8 monomeric units. The monomer units comprising an oligomeric affinity group may be naturally occurring or synthetic, generally being from about 2 to 30 carbon atoms, usually from about 2 to 18 carbon atoms and preferably from about 2 to 12 carbon atoms.

For affinity groups in the library, one or more monomeric units of the oligomer may remain constant, to reduce the overall complexity of the combinatorial library.

If the affinity group is an oligopeptide, the amino acid monomers may be naturally occurring or synthetic. Conveniently, the naturally occurring L- α -amino acids will be used, although the D-enantiomers may also be employed.

While the amino acid monomers of the oligomer may be any one of the 20 naturally occurring amino acids in either the L- or D-configuration, the amino acids employed will preferentially be free of reactive functionalities, particularly reactive functionalities which would react with the reactive functionality (R) of the affinity label compound. Therefore, the amino acids used in the invention will usually be free of reactive amino groups, frequently also being free of thiol groups. Of particular interest are such amino acids as alanine (A), glycine (G), proline (P), valine (V), serine (S), phenylalanine (F), isoleucine (I) and leucine (L) or uncharged polar amino acids like methionine (M). Other suitable amino acids include glutamate, aspartate and

aromatic amino acids, such as histidine (H), tryptophan (W), tyrosine (Y), and arginine (R).

Amino acid monomers of the oligomeric affinity group may also be synthetic. Thus, any unnatural or substituted amino acids of from 4 to 30, usually from 4 to 20,
5 carbon atoms may be employed. Of particular interest are the synthetic amino acids β -alanine and γ -aminobutyrate or functional group protected amino acids such as O-methyl-substituted threonine (T), serine (S), tyrosine (Y), or the like. Various synthetic peptides are disclosed in Stewart, et al., *Solid Phase Peptide Synthesis*, W.H. Freeman, Co., San Francisco (1969); Bodanszky, et al., *Peptide Synthesis*, John Wiley
10 and Sons, Second Edition (1976); J. Meienhofer, *Hormonal Proteins and Peptides*, 2: 46, Academic Press (1983); Merrifield, *Adv. Enzymol.* 32: 221-96 (1969); Fields, et al., *Int. Peptide Protein Res.*, 35: 161-214 (1990) and U.S. Patent 4,244,946 for solid phase peptide synthesis and Schroder, et al., *The Peptides*, Vol. 1, Academic Press (N.Y.) (1965), each of which is hereby incorporated by reference.

Amino acids useful in the present invention may have the carboxyl group at a site other than the terminal carbon atom, the amino group at a site other than the α -position or may be substituted with groups other than oxy, thio, carboxy, amino or guanidino, e.g., cyano, nitro, halo, particularly fluorine, oxo, inorganic acyl groups, etc. Synthetic amino acids may also be monosubstituted on nitrogen as in peptoids,
20 which are oligomers of *N*-substituted glycine residues. *N*-substituted amino acids which find use will have an *N*-substituent of from about 1 to 8 carbon atoms, usually 1 to 6 carbon atoms, which may be aliphatic, alicyclic, aromatic or heterocyclic, usually having not more than about 3 heteroatoms, which may include amino (tertiary or quaternary), oxy, thio, and the like.

Oligopeptides may be constructed by employing standard Merrifield solid phase synthetic methods, manually or by using an automated peptide synthesizer, standard protection chemistry (e.g., *t*-Boc or Fmoc chemistry) and resins (e.g., 4-methyl benzhydryl amine Rink Amide resin). Successive rounds of deprotection of the terminal amino group and coupling of amino acid monomers, followed by
30 deprotection and cleavage of peptides from resins results in the synthesis of

oligopeptides of the desired sequence and length. Additionally, liquid phase peptide synthesis is well known in the art and may also be employed.

If the amino acid monomers employed are *N*-substituted glycine residues, monomers may incorporate *t*-butyl-based side chain and 9-fluorenylmethoxycarbonyl α -amine protection. (See, for example, Gordon, et al., J. of Medicinal Chemistry (1994) 37, 1387-1385, and references cited therein.) Controlled oligomerization of the *N*-substituted monomers may be performed manually and/or robotically with *in situ* activation by either benzotriazol-1-yloxytris (pyrrolidino)-phosphonium hexafluorophosphate or bromotris (pyrrolidino) phosphonium hexafluorophosphate. Additional steps may follow standard automated peptide synthesis protocols using α -(9-fluorenylmethoxycarbonyl) amino acids.

General Connecting Groups (C_a and C_b)

Compositions of the invention may include one or more connecting components between the therapeutic or *in vitro* or *in vivo* diagnostic agent and the affinity group. The connecting groups may provide for synthetic convenience, particular physical characteristics of the total composition, e.g., water solubility, reduced non-specific binding, lipid solubility, and introduction of markers to allow for better identification of the molecule, e.g. dyes, chromophors, fluorophores and radiolabelled elements inclusive of C_{14} and H_3 .

For the most part, the connector(s) will be bifunctional, about 1-20 atoms in length, which atoms may be carbon, nitrogen, oxygen, sulfur, phosphorus, and the like. The connector(s) may be alkylene groups, generally of from 2-16, more usually of from 1-25, carbon atoms, polyoxyalkylene groups, where the alkylene groups will be of 2-3 carbon atoms, and having from 1-8, more usually of from about 1-6, units, an amino acid, including alpha and omega amino acids, or oligopeptide having from 1-8, usually 1-6, amino acids, where the amino acids may be polar or non-polar, charged or uncharged, aliphatic, alicyclic, aromatic or heterocyclic, naturally occurring or synthetic. The connector(s) may also have the structure of an affinity group as described above, thereby providing additional binding affinity at the target site.

General Entities (E)

In general, the entity may be any moiety that may be linked to the reactive group and will covalently bond to the target molecule. Thus, an entity according to the invention can be any of a wide variety of biologically active or non-biologically active compounds that can bond to targets in a complex mixture. Examples of entities that may be particularly useful in the present invention include *in vitro* and *in vivo* diagnostic agents and therapeutic agents.

A. In Vitro Diagnostic Agents

In vitro diagnostic agents find use in *in vitro* diagnostic analysis. Such *in vitro* agents include biotin, fluorophors (such as fluorescein), chromophors, radiolabelled probes and chemiluminescent agents and the like, as recognized by those of skill in the art.

B. In Vivo Diagnostic Agents

In another aspect of the invention, the entity may be a compound which allows the diagnostic visualization of specific sites or compartments within the body by employing such diagnostic techniques as positron emission tomography (PET), computerized tomography (CT), single photon emission computerized tomography (SPECT), magnetic resonance imaging (MRI), nuclear magnetic imaging (NMI), fluoroscopy, ultrasound, etc. For such applications, the entity may comprise one or more contrast agents, radioisotopes of such elements as iodine (I), including ^{123}I , ^{125}I , ^{131}I , etc., barium (Ba), gadolinium (Gd), technetium (Tc), including ^{99}Tc , phosphorus (P), including ^{31}P , iron (Fe), manganese (Mn), thallium (Tl), chromium (Cr), including ^{51}Cr , carbon (C), including ^{11}C , or the like, fluorescently labeled compounds, etc. Such entities are also useful for identifying the presence of particular target sites in a mixture, to label molecules in a mixture, and the like. Various examples are found in U.S. Application 08/588,912 assigned to the assignee of this application and hereby incorporated by reference.

C. Therapeutic Agents.

A variety of suitable therapeutic agents are disclosed in U.S. Patent application Nos. 08/702,127 and 08/477,900, each of which is hereby incorporated by reference. In this regard, entities are generally less than 10,000 in molecular weight. Entities are such that they perform the desired function in the environment in which they become covalently bonded. For the most part, that environment will be an aqueous environment, usually serum or the interstitium. For use as drugs, the entity may be an agonist, an antagonist, a specific binding compound, an enzyme inhibitor (where the enzyme may be either soluble or membrane bound), a metal chelator, a factor supplement, a molecular scavenger, such as vitamin E, or the like. More specifically, the entity may include thrombin inhibitors, such as argatroban (for example see Application Number 08/674,315 which is hereby incorporated by reference), renin inhibitors, ACE inhibitors, inhibitors of the coagulation and complement cascade, serine proteases, $\alpha_v\beta_3$ antagonists, GPIIb/IIIa antagonists, CRF antagonists, or the like.

General Library Synthesis

Combinatorial libraries of affinity groups may be prepared in accordance with conventional ways for producing combinatorial libraries, particularly using a solid support and adding the monomeric components in a stepwise manner. See, for example, U.S. Patents 4,883,092; 5,010,175; 5,182,366 and 5,270,170 and PCT applications WO 92/00091; WO 92/09300; WO 93/06121; WO 93/20242; WO 94/06451; WO 94/06291 and WO 95/28640, as exemplary of a much larger literature of techniques. Preferably, the synthetic chemistry is substantially repetitive with the addition of each monomer unit to the growing oligomer.

For purposes of this disclosure, the subject affinity label compounds will be synthesized by conventional methods, although those of ordinary skill will appreciate that other methods may be used. Synthesizers are commercially available for synthesizing oligonucleotides and oligopeptides, as reflected in the references cited above. In addition, various conventional chemistries may be employed. Depending upon the nature of the functional group, the connector and the entity, synthetic strategies will be devised which allow for synthesis of the affinity marker library molecules at reasonable yields and without the formation of complex mixtures. As

those of skill will appreciate, the particular synthetic strategy will be determined empirically and on a case by case basis. Methods for combining various compounds are well known in the literature and can be employed with advantage. Where precursors to the entity are known, particularly prodrugs for drugs, the precursor or prodrug will frequently indicate the site for attachment and the nature of a linking group. Where prodrugs are not available, the physiologically active molecule may be modified stepwise at different sites, and the activity of the resulting compound determined.

General Library Screening

Initially, one will have a combinatorial library of compounds having varying oligomeric binding determinants to be screened for their affinity to a target molecule or site. Generally, the compounds will represent at least 50 different affinity groups, frequently 100 different affinity groups, usually at least about 500 different affinity groups, preferably at least about 1000 different affinity groups, and may be 10,000 or more different affinity groups, although usually the libraries will have 5,000 or fewer different affinity groups. The library may have greater proportions of one compound over other compounds, but desirably, the relative concentrations will differ by less than about 50%, preferably less than about 25%. For the screening process, the libraries may be divided into smaller units, which will generally range from about 5 to 1,000, frequently from about 5 to 500, usually from about 10 to 500 moieties and more usually from about 10 to 250. During this initial screening process, the library will include a first member of a binding pair (for instance, biotin for the binding pair biotin-avidin), and the first member will be screened with the second member of the binding pair

For identification of affinity marker members of the library having particular affinity for a particular target site relative to other members of the library, as indicated previously, depending upon the size of the library, some or all of the members of the library may be combined with the pure target compound in an appropriate reaction medium. The composition of the medium will vary widely, depending upon the nature of the target compound and the environment in which the subject affinity label

compounds will be used for bonding to the target compound. For the most part, the media will be polar, particularly aqueous, and may be buffered or otherwise modified to more closely mimic the ultimate environment in which the subject compounds will be used. The concentrations of the target compound and the library members may vary widely, usually being determined empirically, so as to optimize the differentiation between the various members of the library. Generally, for screening purposes, concentrations of the target compound will be in the range of about 0.05 to 5 μM , preferably in the range of about 0.1 to 1.0 μM , while concentrations of the library will vary in the range of about 10 to 150 μM , preferably in the range of from about 50 to 100 μM and more preferably in the range of from about 75 to 85 μM .

The temperature of the reaction may vary broadly as long as it is compatible with the reactants' and media stability. The temperature is thus frequently room temperature or the ambient temperature in which the subject compounds will be used. To the extent that the subject compositions will be used physiologically, the temperature will generally be between about 34-40 $^{\circ}\text{C}$, more usually about 37 $^{\circ}\text{C}$.

The determination of affinity for the target exhibited by the various affinity marker members of the library may be made by determining the composition of the liberated affinity groups at a single time point or a plurality of time points after the reaction is initiated. For the most part, those affinity groups which are liberated the earliest after the reaction is initiated are those which exhibit the greater binding affinity for that target site. Usually, the reaction will be allowed to proceed until there is a sufficient population of liberated affinity groups to allow for their ready determination and differentiation. Preferably, the reaction will be interrupted by the addition of a quenching chemical solution, thus allowing the fastest bonding members only to add to the target protein. In general, reactions terminated by quenching at short reaction times are preferred. Due to the large influence of the quenching solution on the behavior of the screening process, the time when the quenching solution is added will be studied as a separate screening parameter. Quenching times of 1 and 15 minutes will be studied. The affinity label leaving groups may be analyzed by any convenient means, including mass spectrometry, gel electrophoresis, chromatography, e.g., HPLC, TLC, or the like, where, if appropriate, the separated components may

then be sequenced. Where a plurality of aliquots of the library used, those sequences demonstrating preferred affinities may then be combined in a subsequent determination for direct comparison.

General Library Screening: Experimental Procedures

The screening of libraries that contain an entity which becomes covalently bonded to the target protein as a result of the affinity labeling reaction described herein may be conducted in two sequential steps and serves as a specific example of a general method for detecting the existence of a covalent adduct. First, a selected target protein reacts with the affinity labeling library or portion thereof. This step is typically conducted at room temperature, although not exclusively so, in the wells of polypropylene 96-well plates. Specified wells contain the target protein typically present at a concentration between 0.1 and 1 μM in a buffered solution of appropriate composition and pH for maintaining the native biological structure and function of the target protein. Labeling reactions are initiated by adding a solution of affinity labeling library members in DMSO to give typical concentrations of total library and DMSO of 80 μM and 2% (volume/volume), respectively. The labeling reactions are terminated at a specified time, as short as 5 seconds or longer than 1 hour, by the addition of a suitable quench reagent (i.e., hydroxylamine for quenching thioesters) that combines with unreacted library members to form other species that do not react with the target protein. As controls, specified wells of the plate contain reaction mixtures that measure the amount of non-covalent binding of the entity to the target protein. These control reactions are conducted by first mixing the library with the quench reagent for a time sufficient to give forms of the library that do not react with the target protein and then adding the target protein.

Second is the detection of the entity that covalently bonds to the target protein, using standard methodologies known in the art, but in a novel time dependent process. For example, if the entity that covalently bonds to the target protein is biotin (or any first binding member of a binding pair), Enzyme-Linked-Immunoassays (ELISA's) can be employed to detect covalent bonding. Briefly, in these assays, polystyrene 96-well plates are coated with an antibody that specifically binds the target protein and

modified forms thereof. A portion of each reaction mixture is then transferred to the corresponding wells of the antibody-coated plate, and the binding of target protein to antibody allowed to ensue for approximately 2 hours. The plate is then emptied and 10 times filled with and emptied of phosphate buffered saline (PBS, 10 mM Pi, pH 7.4, 137 mM NaCl, 2.7 mM KCl) to remove non-covalently bound biotin from the well. A solution containing the enzyme conjugate avidin-horse-radish peroxidase (or any second member of a binding pair) may then be added to each washed well, and the binding of avidin of the conjugate to biotin of the modified target molecule, already bound to the antibody of the plate, is complete after 30 minutes. The plate may then be washed as described above; hydrogen peroxide and orthophenyl diamine are added as substrates of the peroxidase enzyme to give a visual measure of the amount of conjugate present in each well; conjugate amount is proportional to the amount of modified target protein in the well. The optical densities of each well are measured, and the values obtained are recorded in a computer spreadsheet and analyzed.

While the ELISA method of screening described above is specific for biotin-containing proteins, the method is, in principle, applicable for measurement of any affinity labeling library that results in the formation of a detectable adduct with any target biomolecule that can be sequestered at the surface of a 96-well plate.

General *In Vivo* or *In Vitro* Use of an Identified Affinity Group

Once a particular affinity group is identified, the group may be utilized *in vivo* for delivery of therapeutic or diagnostic agents or *in vitro* through coupling to an *in vitro* diagnostic agent for analysis of molecules to which the affinity group associates.

A. *In vitro*

The subject invention thus provides an efficient approach to identifying affinity label compounds that can be used to direct a specific entity to a target site. The subject invention allows for marking specific targets, particularly proteins, for a wide variety of purposes. Where complex mixtures are involved, such as blood, by using the present invention, one can enhance bonding to a specific component in the

blood, more particularly, a specific site on the target. In this way, one may achieve specific targeting to mobile components, such as blood cells, e.g., erythrocytes and platelets, proteins, such as immunoglobulins, serum albumin, transferrin, and the like. In mixtures in culture, one may specifically inhibit an enzyme target, so as to prevent enzymatic interference with the culture. For example, one may provide for specific bonding to RNases to prevent degradation of RNA. One may inhibit specific hydrolases, oxidoreductases, or the like. Where one wishes to mark a particular target, one can utilize fluorescent, radioactive, or other entity, which may be detected.

B. *In vivo*

When administered physiologically, the targets will usually be proteins, either individually, as aggregates with the same or different proteins or as surface membrane proteins.

The subject affinity label compounds, when administered physiologically, will usually be administered as a bolus, but may be introduced slowly over time by transfusion using metered flow, or the like. Alternatively, although less preferable, blood may be removed from the host, contacted with the affinity label compound *ex vivo*, and returned to the host. The affinity label compounds will be administered in a physiologically acceptable medium, e.g., deionized water, phosphate buffered saline, saline, mannitol, aqueous glucose, alcohol, vegetable oil or the like. Usually, a single injection will be employed, although more than one injection may be used, if desired. The affinity label compounds may be administered by any convenient means, including syringe, catheter or the like. The particular manner of administration will vary depending upon the amount to be administered, whether a single or sequential bolus, or continuous administration, or the like. Administration will be intravascular, where the site of introduction is not critical to this invention, preferably at a site where there is rapid blood flow, e.g., intravenously, peripheral or central vein. The intent is that the compound administered be effectively distributed in the vascular system so as to be able to react with target molecules therein.

The dosage of the affinity label compound will depend upon the entity employed and will, therefore, depend on the adverse effects of the entity, if any, the time necessary to reduce the unbound concentration of the affinity label compound present in the vascular system, the indication being sought, the sensitivity of the compound to destruction by vascular components, the route of administration and the like. As necessary, the dosage of affinity label compound may be determined empirically, initially using a small multiple of the dosage normally administered, and as greater experience is obtained, enhancing the dosage. Dosages will generally be in the range of 1 ng/kg to 10 mg/kg, usually being determined empirically in accordance with known ways, as provided for in preclinical and clinical studies.


The following examples are offered by way of illustration, and not by way of limitation.

Examples

In this section, we first describe the construction of S-, O-, and N-linked affinity label libraries: examples 1, 2, and 3 respectively. We then show the results for screening of an S-linked library against HSA at the level of 81 compounds per well (example 4), 9 compounds per well (example 5), and 1 compound per well (example 6). The results of these experiments indicate that -F/YEE is the preferred affinity group for bonding to HSA. Next, results of experiments characterizing the bonding of biotin to HSA using a -F/YEE affinity group are shown. Specifically, example 7 describes methods and materials used for the biological experiments and in examples 8 through 14, we show the results of these experiments.

Example 1: Construction of S-linked Affinity Label Libraries


A representative affinity label library according to the invention and having a *p*-thiobenzoic acid residue as a reactive group and a thioester bond as a reactive functional group was designed and constructed. The structure of the library is as follows:




An example of an S-linked library member is Biotin-SPhCO-O₁-O₂-X₁-X₂-B-NH₂, in which there is no C_a.

In the above described structure, X₁ and X₂ represent that all of the 9 selected L-amino acids appear in a well, O₁ represents that only one of the 9 selected L-amino acids appear in a well, O₂ represents that only one of the 9 selected D-amino acids appears in a well, and B represents that only one of the 9 selected L-amino acids appears in all 81 wells of a set. Biotin serves as the "entity," as described herein. The "SPhCO" represents a *p*-thiobenzoyl reactive group R between the biotin "entity" and an oligomeric affinity group (O₁-O₂-X₁-X₂-B-NH₂).


Biotin is represented by the following structure:




Biotinyl is represented by the following structure:



Thiobenzoyl is represented by the following structure:



S-9-Fluorenylmethyl *p*-thiobenzoic acid (Fm-S-Ph-CO₂H) is represented by the following structure:



The precursor for Fm-S-Ph-CO₂H, 9-fluorenylmethyl chloride (Fm-Cl), was synthesized as follows. A solution of 25.0 g 9-fluorenylmethanol (127 mmol, Aldrich Chemical) was refluxed with 150 mL thionyl chloride for 30 minutes. The excess thionyl chloride was removed by distillation and the residue distilled at reduced pressure, then crystallized from ethanol two times to afford 19.2 g 9-fluorenylmethyl chloride (89.4 mmol, 70%) as a pale yellow solid.

Fm-S-Ph-CO₂H was prepared as follows: To a 0 °C suspension of 3.40 g 4-mercaptobenzoic acid (85%, Toronto Research Chemicals) (18.7 mmol) in 60 mL *N,N*-dimethylformamide (DMF) was added 4.00 g 9-fluorenylmethyl chloride (Fm-Cl) (Bodansky, M.; Bednarek, M. A. *Int. J. Pept. Protein Res.* **1982**, 20, 434) synthesized as described above, (18.7 mmol) and 6.90 mL diisopropylethylamine (37.4 mmol). The reaction was allowed to slowly warm to RT and then stirred for 16 h. The cloudy yellow-brown solution was washed with hexanes (3 x 50 mL), diluted with 50 mL 1M HCl and extracted with ethylacetate (3 x 50 mL), washed with 50 mL sat. aq. NaCl,

dried with anhyd. MgSO_4 , filtered, and concentrated via rotary evaporation to afford a yellow-brown oil. This oil was then dissolved in 20 mL MeOH, cooled to -20°C and the resulting crystals were collected by filtration, washed with ice cold MeOH and dried to afford 5.59 g of Fm-S-Ph- CO_2H as a white solid (13.0 mmol, 70%).

The nine amino acids employed were carefully selected by considerations of the side chain functional groups and are listed in Table 1.

TABLE 1

	Code	Amino Acid	Category	Starting Material
10	1	glutamic acid	acid	Fmoc-Glu(OtBu)-OH
	2	glutamine	amide	Fmoc-Gln(Trt)-OH
	3	arginine	base	Fmoc-Arg(Pmc)-OH
	4	methionine	sulfide	Fmoc-Met-OH
	5	serine	alcohol	Fmoc-Ser(tBu)-OH
15	6	tyrosine	phenol	Fmoc-Tyr(tBu)-OH
	7	leucine	aliphatic	Fmoc-Leu-OH
	8	phenylalanine	aromatic	Fmoc-Phe-OH
	9	tryptophan	aromatic	Fmoc-Trp(Boc)-OH

The D-amino acids, O_2 , were introduced in order to prevent facile peptidyl cleavage *in vivo* and to maximize the affinity to the macromolecular targets.

In each set, there are 81 wells and in each well, there are 81 compounds while B is fixed. Such results in a library of 6561 total library members.

For example, when glutamic acid (E) was chosen to be the residue "B" in the above formula, the set 1 of combinatorial p-thiobenzoyl-containing affinity labeling libraries Biotin-SPhCO- $\text{O}_1\text{-O}_2\text{-X}_1\text{-X}_2\text{-E-NH}_2$ was constructed as follows:

The synthesis utilized Merrifield solid phase peptide synthesis methods and Fmoc chemistry. Rink amide MBHA resin was used to furnish amide at the C-terminus.

A schematic illustration outlining the construction of this set of libraries described above is shown in Figure 3.

In step (1) shown in Figure 3, Fmoc-Glu(OtBu)-OH was coupled to an identical amount of resin support in all 9 reaction vessels after removal of the Fmoc protecting group on Rink amide MBHA resin.

Removal of the Fmoc group was performed by treating with 20% piperidine in *N*-methylpyrrolidinone (NMP) twice, 2 minutes and 15 minutes, respectively at room temperature, followed by several NMP washes.

Coupling of the Fmoc-Glu(OtBu)-OH to the resin support was performed by adding to the resin in a reaction vessel with an *N,N*-dimethylformamide (DMF) solution of the amino acid (4 equivalents), *o*-benzotriazol-1-yl-*N,N,N'*-tetramethyluronium hexafluorophosphate (HBTU) (4 equivalents), 1-hydroxybenzotriazole (HOBt) (4 equivalents) and diisopropylethyl amine (DIEA) (8 equivalents). The reactions were allowed to proceed for 2 hours at room temperature. Completion of each reaction was monitored by a ninhydrin test to detect the presence of unreacted amino groups. The coupling reactions were repeated until the ninhydrin test for each reaction was negative. Once coupling was complete, as evidenced by a negative ninhydrin test, the peptide resin in each of the nine separate reactions was washed repeatedly with DMF.

Before the second L-amino acids were coupled to an identical amount of resin bearing the same Fmoc protected amino acid (i.e., Fmoc-Glu(OtBu)-OH) in all 9 reaction vessels), the Fmoc protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 15 minutes, respectively, at room temperature, followed by several NMP washes.

As shown in step (2) of Figure 3, each of the nine different Fmoc-protected L-amino acids shown in Table 1 were then individually linked to an identical amount of resin in all 9 reaction vessels. Coupling reactions were again carried out by adding to the resin in a reaction vessel with a DMF solution of the amino acid (4 equivalents),

5 HBTU (4 equivalents), HOBt (4 equivalents) and DIEA (8 equivalents). The reactions were allowed to proceed for 2 hours at room temperature. Completion of each reaction was monitored by a ninhydrin test. The coupling reactions were repeated until the ninhydrin test for each reaction was negative. Once coupling was complete as evidenced by negative ninhydrin test, the peptidyl resin in each of the nine separate reactions was washed with DMF.

10 The result of this second round of coupling is the generation of nine equimolar independent and distinct pools of dipeptides linked to resin support. As shown in Figure 3, since each of the nine independent and distinct pools contains one distinct dipeptide, there are now 9 distinct dipeptides generated.

As shown in step (3) of Figure 3, the resins from each of the nine independent and distinct pools generated in step (2) were mixed and then divided into identical pools. This gives rise to nine identical pools, each consisting of nine distinct dipeptides linked to the resin support.

15 Before the third round of coupling, the Fmoc protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 15 minutes, respectively, at room temperature, followed by several NMP washes.

As shown in step (4) of Figure 3, each of the nine different Fmoc-protected L-amino acids shown in Table 1 were individually linked to an identical pool of resin in all nine reaction vessels. Coupling reactions were carried out as described above.

20 As shown in step (5) of Figure 3, the resins from each of the nine independent and distinct pools generated in step (4) were mixed and then divided into identical pools, producing nine identical pools, each consisting of 81 distinct tripeptides linked to the resin support.

25 Before the fourth round of coupling, the Fmoc protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 15 minutes, respectively at room temperature, followed by several NMP washes.

As shown in step (6) of Figure 3, each of the nine different Fmoc-protected amino acids shown in Table 1 were linked to an identical pool of resin in all nine reaction vessels. In this round of coupling, unlike any of the other round of coupling,

amino acids in the D-configuration are employed. Coupling reactions were again carried out as described above.

5 This fourth round of coupling generates nine equimolar independent and distinct pools of tetrapeptides linked to resin support. As shown in Figure 3, since each of the nine independent and distinct pools contains 81 distinct tetrapeptides, there are now 729 distinct tetrapeptides generated.

10 As shown in step (7) of Figure 3, each of the nine independent and distinct pools of tetrapeptides generated in step (6) were each divided into a set of nine identical pools without mixing the pools before dividing, giving rise to nine sets of identical pools (81 pools total), each pool containing 81 tetrapeptides. The step of splitting the pools without mixing permits the fourth and fifth amino acids coupled to the resin to be defined. Before the fifth round of coupling, the Fmoc protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 15 minutes, respectively, at room temperature, followed by several NMP washes.

15 As shown in step (8) of Figure 3, each of the nine identical pools in each of the nine sets of pools generated in step (7) was then coupled by one of the nine Fmoc-protected amino acids shown in Table 1. Coupling reactions were again carried out as described above.

20 This fifth round of coupling generates eighty-one equimolar independent and distinct pools of pentapeptides linked to a resin support. As shown in Figure 3, since each of eighty-one independent and distinct pools contains eighty-one distinct pentapeptides, 6561 distinct pentapeptides have been generated.

25 As shown in step (9) of Figure 3, each of the eighty-one independent and distinct pools generated in step (8) was then coupled to S-9-fluorenylmethyl- *p*-thiobenzoic acid (Fm-S-Ph-CO₂H). Before the coupling of Fm-S-Ph-CO₂H, the Fmoc protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 15 minutes, respectively at room temperature, followed by several NMP washes.

30 Coupling reactions were carried out by adding to the resin in a reaction vessel with a DMF solution of S-9-fluorenylmethyl-*p*-thiobenzoic acid (4 equivalents), HBTU (4 equivalents), HOBT (4 equivalents) and DIEA (8 equivalents). The reactions

were allowed to proceed for 2 hours at room temperature. Completion of each reaction was monitored by a ninhydrin test. The coupling reactions were repeated until the ninhydrin test for each reaction was negative. Once coupling was complete as evidenced by a negative ninhydrin test, the peptidyl resin in each of the nine
5 separate reactions was washed with DMF.

Before the last round of coupling, the fluorenylmethyl protecting group was removed by treating with 20% piperidine in NMP twice, 2 minutes and 10 minutes, respectively at room temperature, followed by NMP washes rapidly.

As shown in step (10) of Figure 3, each of eighty-one independent and distinct
10 pools generated in step (8) was then coupled to biotin. Coupling reactions were carried out by adding to the resin in a reaction vessel with a DMF solution of biotin (5 equivalents), HBTU (5 equivalents), HOBt (5 equivalents) and DIEA (10 equivalents). The reactions were allowed to proceed for 2 hours at room temperature. The coupling reactions were repeated to ensure completion.

Finally, to complete the construction of the *p*-thiobenzoyl-containing affinity
15 labeling libraries, as shown in step (11) of Figure 3, the completely constructed affinity labeling libraries were cleaved from the resin component and cleavage and purification were performed as follows.

The peptidyl resin mixtures in each 81 independent and distinct pools
20 generated in step (10) were dried and then independently treated with trifluoroacetic acid (TFA)/H₂O (95/5, v/v) for 1.5 hours. The peptide/TFA solutions were then precipitated then washed with ether. Following ether precipitation, the peptide solutions were suspended in 0.045% TFA in water and lyophilized, to yield the completely constructed and dried *p*-thiobenzoyl-containing affinity labeling library.


The final combinatorial *p*-thiobenzoic-containing affinity labeling library is
25 substantially stable under normal storage conditions as determined by mass spectral analysis.

Example 2: Construction of O-Linked Affinity Labeling Libraries


In addition to S-linked libraries, O-linked libraries can be synthesized having a
30 *p*-hydroxybenzoic acid as a reactive functional group. Individual solid phase peptide

synthesis is performed on an Applied Biosystems 433A Peptide Synthesizer using FastMoc Chemistry. Multiple peptide syntheses are performed on a Gilson AMS 422 Multiple Peptide Synthesizer using Fmoc chemistry. Solid phase reactions were monitored by ninhydrin test for completion. Amino acids and Rink Amide MBHA resin were obtained from NovaBiochem. Preparative HPLC was performed on a 21.4 x 250 mm C₁₈ reverse phase column using 5-60% B (0.045% TFA in H₂O and 0.045% TFA in CH₃CN) gradient elution. Liquid Chromatography/Mass Spectrometry results were obtained using electrospray ionization on a Perkin Elmer Sciex API300 Mass Spectrometer using a 1.0 x 250 mm C₁₈ reverse phase protein/peptide column using 0-70% B (0.045% TFA in H₂O and 0.045% TFA in CH₃CN) gradient elution.

The structure of *p*-hydroxybenzoyl is as follows:



The structure of Fmoc-OPh-CO₂H is as follows:



Synthesis of 9 Individual Library Members

Synthesis was performed on the Gilson AMS 422 Multiple Peptide Synthesizer using 25 μ mol Rink amide MBHA resin/reaction tube. Deprotection of the Rink amide MBHA resin and subsequent deprotections of the Fmoc amino acids were

carried out using 25% piperidine in *N,N*-dimethylformamide (DMF) (4 x 5 min each) followed by a DMF wash (6 times). Coupling of the amino acids, each dissolved in *N*-methylpyrrolidinone (NMP), was performed two using 300 μ L of 0.68 M amino acid solution (8 eq) in *N*-methylpyrrolidinone (NMP), 440 μ L of 0.45 M solution of *o*-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt) (8 eq) in DMF, and 100 μ L of 4 M *N*-methylmorpholine (NMM) (16 eq) in DMF were added and allowed to react for 1 h. Upon completion, dichloromethane (DCM) was added and reaction continued for 1 h. The reaction mixtures were then filtered and washed with DMF (6 times) and the next amino acid coupling was performed. The first coupling reaction was Glu, the second was one of nine different amino acids (Glu, Gln, Arg, Met, Ser, Tyr, Leu, Phe, and Trp), one amino acid/tube, the third coupling was Tyr, followed by D-Leu, then Phe.

The addition of the O-Ph group was performed in exactly the same way as an amino acid coupling. First, the last amino acid added was deprotected and washed, then 300 μ L of 0.68 M Fmoc-O-Ph-CO₂H (8 eq) in DMF, 440 μ L of a 0.45 M solution HBTU/ HOBt (8 eq) in DMF, and 100 μ L of 4 M NMP (16 eq) in DMF were added and allowed to react for 1 h. Then, DCM was added and reaction continued for 1 h, followed by the removal of the Fmoc group with 25% piperidine in DMF.

Biotin was added by reacting 980 μ L of a 128 mM biotin isobutyl carbonic anhydride (5 eq) solution (2 x 10 h each). The resins were then washed with DMF (6 times) and DCM (6 times).

Each of the peptidyl resin mixtures was then independently treated with 0.75 mL trifluoroacetic acid (TFA):H₂O:phenol (10:0.5:0.75, v/v/wt) (2 x 1 h each), washed with 0.75 mL TFA and 0.75 mL DCM. The combined filtrates were then concentrated via speed vac and products isolated by precipitation with dry-ice cold Et₂O (3 mL) followed by centrifugation. The resulting white solids were then washed with dry-ice cold Et₂O (2 x 3 mL each), then dissolved in 1.5 mL of 0.045% TFA in H₂O and 1.5 mL of 0.045% TFA in CH₃CN, allowed to stand at RT for 1 h then purified by reverse phase prep HPLC to afford the products, after lyophilization, as white solids.


Synthesis of biotin isobutyl carbonic anhydride

In a 50-mL round-bottomed flask equipped with a magnetic stir bar and N₂ inlet adapter was dissolved 822 mg biotin (3.30 mmol) in 23.9 mL hot DMF. After cooling to room temperature, 1.38 mL triethylamine (9.90 mmol) was added followed immediately by 428 μ L isobutylchloroformate (3.30 mmol). Immediately, a precipitate formed and the reaction was allowed to stir at RT for 10 min. The insoluble precipitate (TEA•HCl) was removed by filtration to afford the approximately 128 mM biotin isobutyl carbonic anhydride solution.


Example 3: Construction of N-Linked Affinity Labeling Libraries

In addition to S-linked and O-linked libraries, N-linked libraries can be synthesized having a *p*-aminobenzoic acid as a functional group. Individual solid phase peptide syntheses can be performed on an Applied Biosystems 433A Peptide Synthesizer using FastMoc Chemistry. Multiple peptide syntheses can be performed on a Gilson AMS 422 Multiple Peptide Synthesizer using Fmoc chemistry. Solid phase reactions can be monitored by ninhydrin test for completion. Amino acids and Rink Amide MBHA resin can be obtained from NovaBiochem. Preparative HPLC can be performed on a 21.4 x 250mm C₁₈ reverse phase column using 5-60% B (0.045% TFA in H₂O and 0.045% TFA in CH₃CN) gradient elution. Liquid Chromatography/Mass Spectrometry analysis can be obtained using electrospray ionization on a Perkin Elmer Sciex API300 Mass Spectrometer using a 1.0 x 250 mm C₁₈ reverse phase protein/peptide column using 0-70% B (0.045% TFA in H₂O and 0.045% TFA in CH₃CN) gradient elution.

The structure of *p*-aminobenzoyl is as follows:



The structure of Fmoc-HNPh-CO₂H is as follows:



Synthesis of 9 Individual Library Members

Synthesis can be performed on the Gilson AMS 422 Multiple Peptide Synthesizer using 25 μ mol Rink amide MBHA resin/reaction tube. Deprotection of the Rink amide MBHA resin and subsequent deprotections of the Fmoc amino acids can be carried out using 25% piperidine in *N,N*-dimethylformamide (DMF) (4 x 5 min each) followed by a DMF wash (6 times). Coupling of the amino acids, each dissolved in *N*-methylpyrrolidinone (NMP), can be performed two using 300 μ L of 0.68 M amino acid solution (8 eq) in NMP, 440 μ L of 0.45 M solution of *o*-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt) (8 eq) in DMF, and 100 μ L of 4 M *N*-methylmorpholine (NMM) (16 eq) in DMF are then added and allowed to react for 1 h. Upon completion, dichloromethane (DCM) was added and the reaction continued for 1 h. The reaction mixtures are then filtered and washed with DMF (6 times) and the next amino acid coupling was performed. The first coupling reaction can be Glu, the second was one of nine different amino acids (Glu, Gln, Arg, Met, Ser, Tyr, Leu, Phe, and Trp), one amino acid/tube, the third coupling was Tyr, followed by D-Leu, then Phe.

The addition of the N-Ph group can be performed in exactly the same way as an amino acid coupling. First, the last amino acid added is deprotected and washed, then 300 μ L of 0.68 M Fmoc-NH-Ph-CO₂H-S-Ph-CO₂H (8 eq) in DMF, 440 μ L of 0.45 M solution HBTU/HOBt (8 eq) in DMF, and 100 μ L of 4 M NMP (16 eq) in DMF are added and allowed to react for 1 h. Upon completion, DCM is added and reaction continued for 1 h, followed by the removal of the Fmoc group with 25% piperidine in DMF.

Biotin is added by reacting 980 μL of a 128 mM biotin carbonic anhydride (5 eq) solution (2 x 10 h each). The resins are then washed with DMF (6 times) and DCM (6 times).

Each of the peptidyl resin mixtures can then independently treated with 0.75 mL trifluoroacetic acid (TFA): H_2O :phenol (10:0.5:0.75, v/v/wt) (2 x 1 h each), washed with 0.75 mL TFA and 0.75 mL DCM. The combined filtrates are then concentrated via speed vac and products isolated by precipitation with dry-ice cold Et_2O (3 mL) followed by centrifugation. The resulting white solids are then washed with dry-ice cold Et_2O (2 x 3 mL each), then dissolved in 1.5 mL of 0.045% TFA in H_2O and 1.5 mL of 0.045% TFA in CH_3CN , allowed to stand at RT for 1 h then purified by reverse phase prep HPLC to afford the products, after lyophilization, as white solids.

Synthesis of Individual Compounds

Biotin Isobutylcarbonic Anhydride Solution

In a 10-mL round-bottomed flask equipped with a magnetic stir bar and N_2 inlet adapter was dissolved 300 mg of biotin (1.23 mmol) in 5 mL of hot DMF. This was allowed to cool to RT where 677 μL of triethylamine (4.86 mmol) was added followed immediately by 160 μL of isobutylchloroformate (1.23 mmol). Immediately, a precipitate formed and the reaction was allowed to stir at RT for 10 min. The insoluble precipitate ($\text{TEA}\cdot\text{HCl}$) was removed by filtration and washed with 2-mL of DMF to afford 8 mL of the approximately 154 mM biotin carbonic anhydride solution containing approximately 453 mM TEA (3.63 mmol).

Synthesis of Biotin-OPH-CO-F/YEE-NH₂

The procedure followed for this synthesis is illustrated schematically in Figure 16. Synthesis of the fragment HO-Ph-CO-F/YEE-PS was synthesized using Applied Biosystems 433A peptide synthesizer using FastMoc chemistry (HBTU/HOBt/DIEA) with final deprotection on a 0.250 mmol scale using Fmoc-Rink amide MBHA resin (NovaBiochem) in 98% yield. The resulting fragment was then transferred to a 20-mL glass solid phase reaction vessel and washed with three 4-mL portions of DMF. This

was then shaken with 8 mL of an approximately 150 mM solution of biotin
 isobutylcarbonyl anhydride solution (1.23 mmol) with approximately 453 mM TEA
 (3.63 mmol) for 70 h. This was then filtered and washed with six 4-mL portions of
 DMF and three 4-mL portions of DCM. The resin was then treated with two 4-mL
 5 portions of cleavage cocktail solution (10 mL TFA, 0.5 mL water and 0.75 g phenol)
 for 1 h each. The resin was then washed with 4 mL TFA and 4 mL DCM and the
 combined cleavage and washing filtrates were concentrated by rotary evaporation to 2
 mL. The crude product was then isolated by precipitation with 30 mL dry-ice cold
 Et₂O followed by centrifugation. After decanting the supernatant, the resulting white
 10 solid was re-suspended in 30 mL dry-ice cold ether, centrifuged, and decanted two
 times. This was then dissolved in 10 mL of 0.045% TFA in CH₃CN and 10 mL of
 0.045% TFA in water, allowed to stand at RT for 1 h, frozen and lyophilized to afford
 219 mg of the crude product as a white solid. Analytical HPLC reveals product to be
 approximately 80% pure (contains approximately 10% HO-Ph-CO-F/YEE-NH₂).
 15 This was then purified by preparative reverse-phase HPLC to afford 121 mg of biotin-
 OPh-CO-F/YEE-NH₂ as a white solid (0.115 mmol, 47%). ¹H NMR (500 MHz,
 DMSO-d₆) δ 12.05 (br s, 2 H), 9.06 (br s, 1 H), 8.57 (d, *J* = 8.0 Hz, 1 H), 8.19-8.17
 (m, 3 H), 7.84-7.81 (m, 3 H), 7.32 (d, *J* = 7.4 Hz, 1 H), 7.28 (br s, 1 H), 7.24 (t, *J* = 7.5
 Hz, 2 H), 7.17 (d, *J* = 8.7 Hz, 2 H), 7.14 (d, *J* = 7.2 Hz, 1 H), 7.07 (br s, 1 H), 7.00 (m,
 20 3 H), 6.58 (d, *J* = 8.4 Hz, 2 H), 6.44 (br s, 1 H), 6.35 (br s, 1 H), 4.73-4.70 (m, 1 H),
 4.47-4.43 (m, 1 H), 4.33-4.30 (m, 1 H), 4.30-4.20 (m, 2 H), 4.20-4.14 (m, 2 H), 3.16-
 3.12 (m, 1 H), 3.04 (dd, *J* = 13.5, 5.0 Hz, 1 H), 2.97-2.93 (m, 2 H), 2.83 (dd, *J* = 12.5,
 5.0 Hz, 1 H), 2.64-2.54 (m, 4 H), 2.30-2.24 (m, 2 H), 2.20 (t, *J* = 8.0 Hz, 2 H), 1.95-
 1.85 (m, 2 H), 1.85-1.76 (m, 1 H), 1.76-1.70 (m, 1 H), 1.70-1.60 (m, 3 H), 1.56-1.42
 25 (m, 1 H), 1.42-1.35 (m, 2 H), 1.16-1.12 (m, 3 H), 0.71 (d, *J* = 6.0 Hz, 3 H), 0.69 (d, *J* =
 6.0 Hz, 3 H). Anal. HPLC indicated product to be >95% pure with *R*_t = 48.34 min.
 ESI-MS *m/z* for C₅₁H₆₅N₈O₁₄S (MH⁺), calcd 1045.4, found 1045.8.

***N*-Tritylglycine Isobutylcarbonyl Anhydride Solution**

30 In a 10-mL round-bottomed flask equipped with a magnetic stir bar and N₂
 inlet adapter was dissolved 333 mg *N*-trityl glycine (Aldrich) (1.05 mmol) in 2 mL

DCM. To this was added 558 μ L triethylamine (4.86 mmol) was added followed immediately by 130 μ L isobutylchloroformate (1.23 mmol). Immediately, a precipitate formed and the reaction was allowed to stir at κ T for 5 min. The insoluble precipitate (TEA \cdot HCl) was removed by filtration and washed with 2 mL DCM to afford approximately 5 mL of the approximately 200mM *N*-tritylglycine isobutylcarbonic anhydride solution containing approximately 600 mM TEA (3.00 mmol).

Synthesis of Biotin-Gly-O ϕ -CO-F/YEE-NH₂

The procedure for this synthesis is illustrated schematically in Figure 17. Synthesis of the fragment HO- ϕ -CO-F/YEE-PS was synthesized using Applied Biosystems 433A peptide synthesizer using FastMoc chemistry (HBTU/HOBt/DIEA) with final deprotection on a 0.250 mmol scale using Fmoc-Rink amide MBHA resin (NovaBiochem) in 98% yield. A 354 mg portion of the resulting fragment was then transferred to an 8-mL solid phase reaction vessel and washed with three 4-mL portions of DCM. This was then shaken with 5 mL of an approximately 200 mM solution of *N*-tritylglycine isobutylcarbonic anhydride solution (1.23 mmol) with approximately 600 mM TEA (3.63 mmol) for 24 h. This was then filtered and washed with six 2-mL portions of DCM, then treated with five 2-mL portions of (100:5:5) DCM/TFA/TIS (dichloromethane/trifluoroacetic acid/triisopropylsilane) for 2 min each and washed with six 2-mL portions of DCM, three 2-mL portions of DMF, 2 mL of 2 M DIEA in NMP and three 2-mL portions of DMF to afford a pale tan resin. This was then shaken with a solution of 122 mg biotin (0.500 mmol) in 1.10 mL of 0.45 M HBTU/HOBt in DMF, 250 μ L of 2 M DIEA in NMP, and 1.10 mL DMF (heat was required for dissolution) for 1 h. The resin was then filtered and washed with six 2-mL portions of DMF and three 2-mL portions of DCM. The resin was then treated with two 2-mL portions of cleavage cocktail solution (10 mL TFA, 0.5 mL water and 0.75 g phenol) for 1.5 h each. The resin was then washed with 2 mL TFA and 2 mL DCM and the combined cleavage and washing filtrates concentrated by rotary evaporation to 2 mL. The crude product was then isolated by precipitation with 40 mL dry-ice cold Et₂O followed by centrifugation. After decanting the supernatant, the

resulting white solid was re-suspended in 40 mL dry-ice cold ether, centrifuged, and decanted two times. This was then dissolved in 6 mL of 0.045% TFA in CH₃CN and 6 mL of 0.045% TFA in water, allowed to stand at RT for 1 h, frozen and lyophilized to afford the crude product as a white solid. This was then purified by preparative reverse-phase HPLC to afford 29.4 mg of biotin-Gly-Oph-CO-F/YEE-NH₂ as a white solid (0.027 mmol, 21%). Anal. HPLC indicated product to be >95% pure with R_t = 45.43 min. ESI-MS *m/z* for C₅₃H₆₈N₉O₁₅S (MH⁺), calcd 1102.5, found 1103.0.

LC-Biotin Isobutylcarbonic Anhydride Solution

In a 10-mL round-bottomed flask equipped with a magnetic stir bar and N₂ inlet adapter was dissolved 108 mg of *N*-(+)-biotin-6-aminocaproic acid (0.302 mmol) in 6 mL of hot DMF. This was allowed to cool to RT where 167 μ L of triethylamine (1.20 mmol) was added followed immediately by 39.2 μ L of isobutylchloroformate (0.302 mmol). The reaction was then allowed to stir at RT for 10 min to afford approximately 6.2 mL of the approximately 50 mM LC-biotin isobutylcarbonic anhydride solution containing approximately 145 mM TEA (0.898 mmol).

Synthesis of LC-Biotin-Oph-CO-F/YEE-NH₂

The procedure followed for this synthesis is illustrated schematically in Figure 18. Synthesis of the fragment HO-Ph-CO-F/YEE-PS (PS is polystyrene) was synthesized using Applied Biosystems 433A peptide synthesizer using FastMoc chemistry (HBTU/HOBt/DIEA) with final deprotection on a 0.250 mmol scale using Fmoc-Rink amide MBHA resin (NovaBiochem) in 98% yield. A 0.120 mmol portion of the resulting fragment was then transferred to an 8-mL solid phase reaction vessel and washed with three 4-mL portions of DMF. This was then shaken with approximately 6.2 mL of approximately 50 mM solution of LC-biotin isobutylcarbonic anhydride solution (0.302 mmol) with approximately 145 mM TEA (0.898 mmol) for 21 h. This was then filtered and washed with six 2-mL portions of DMF and three 4-mL portions of DCM. The resin was then treated with two 1.5-mL portions of cleavage cocktail solution (10 mL TFA and 0.5 mL water) for 1.25 h each. The resin was then washed with 2 mL TFA and 2 mL DCM and the combined

cleavage and washing filtrates were concentrated by rotary evaporation to 1.5 mL. The crude product was then isolated by precipitation with 13 mL dry-ice cold Et₂O followed by centrifugation. After decanting the supernatant, the resulting white solid was re-suspended in 13 mL dry-ice cold ether, centrifuged, and decanted two times, then dried to afford 98.1 mg of a white solid. Analytical HPLC reveals product to be approximately 52% pure (contains approximately 48% HO-Ph-CO-F/YEE-NH₂). This was then dissolved in 4 mL of 0.045% TFA in CH₃CN and 4 mL of 0.045% TFA in water and purified by preparative reverse-phase HPLC to afford 47.2 mg of LC-biotin-OPh-CO-F/YEE-NH₂ as a white solid (0.041 mmol, 34%). Anal. HPLC indicated product to be >95% pure with R_t = 48.08 min. ESI-MS *m/z* for C₅₇H₇₆N₉O₁₅S (MH⁺), calcd 1158.5, found 1158.8.

***N*-Tritylglycine 4-Nitrophenylcarbonic Anhydride Solution**

In a 10-mL round-bottomed flask equipped with a magnetic stir was dissolved 86.4 mg DMAP (*N,N*-dimethylaminopyridine) (0.708 mmol) in 1 mL EtOAc and 3 mL DCM. To this was added a solution of 36.2 mg 4-nitrophenylchloroformate (0.180 mmol) in 1 mL EtOAc, followed by a solution of 56.2 mg *N*-trityl glycine (Aldrich) (0.177 mmol) in 1 mL DCM. The reaction was then allowed to stir at RT for 15 min. The reaction was then concentrated *in vacuo*, then taken up in 1 mL DMF to afford the approximately 177 mM solution of *N*-tritylglycine 4-nitrophenylcarbonic anhydride containing approximately 531 mM DMAP.

Synthesis of Argatroban-AEA₃-βAla-Gly-OPh-CO-F/YEE-NH₂•2TFA

The procedure followed for this synthesis is illustrated schematically in Figure 19. A 0.035 mmol portion of the HO-Ph-CO-F/YEE-PS fragment was then transferred to a 4-mL solid phase reaction vessel and washed with three 1-mL portions of DMF. This was then shaken with approximately 1.0 mL of approximately 177 mM solution *N*-tritylglycine 4-nitrophenylcarbonic anhydride solution (0.177 mmol) with approximately 531 mM DMAP (0.531 mmol) for 2 h. This was then filtered and washed with six 2-mL portions of DMF and six 2-mL portions of DCM. The trityl group was then removed by vortexing a solution of 5% TFA/5% TIS in DCM (4 x 1

mL) for 1 min each. The resin was then washed with six 1-mL portions of DCM, six 1-mL portions of DMF, 1 mL of 2 M DIEA in NMP, and three 1-mL portions of DMF to afford a tan resin (the resulting resin showed a positive ninhydrin test). The resin was then treated with a solution of 38.0 mg of a 70:30 mixture of argatroban-AEA₃-βAla-OH: argatroban-AEA₃-βAla-NHS ester dissolved in a solution of 393 μL of 0.45 M HBTU/HOBt, 393 μL DMF, and 88.5 μL of 2 M DIEA in NMP for 1.25 h. The resin was washed with six 1-mL portions of DMF and six 1-mL portions of DCM to afford a tan resin (the resulting resin showed a negative ninhydrin test). The resin was then treated with two 1-mL portions of cleavage cocktail solution (10 mL TFA, 0.5 mL water and 0.5 mL TIS) for 1 h each. The combined cleavage filtrates were concentrated by rotary evaporation to 0.5 mL and crude product was then isolated by precipitation with 13 mL dry-ice cold Et₂O followed by centrifugation. After decanting the supernatant, the resulting white solid was re-suspended in 13 mL dry-ice cold ether, centrifuged, and decanted two times. This was then dissolved in 2 mL of 0.045% TFA in CH₃CN and 3 mL of 0.045% TFA in water, allowed to stand at RT for 1 h, frozen then lyophilized to afford 29.7 mg of a white solid. This was then dissolved in 4 mL of 0.045% TFA in CH₃CN and 4 mL of 0.045% TFA in water and purified by preparative reverse-phase HPLC to afford 6.7 mg of argatroban-AEA₃-βAla-Gly-OPh-CO-F/YEE-NH₂ • 2 TFA as a white solid (0.003 mmol, 10%). Anal. HPLC indicated product to be >80% pure with R_t = 54.77 min. ESI-MS *m/z* for C₈₁H₁₁₃N₁₇O₂₄S (MH⁺), calcd 1739.8, found MH²⁺ 871.1.

Synthesis of Fluorescein-thiourea-AEA₃-Gly-OPh-CO-F/YEE-NH₂

The procedure followed for this synthesis is illustrated schematically in Figure 20. A 0.035 mmol portion of the HO-Ph-CO-F/YEE-PS fragment was then transferred to a 4-mL solid phase reaction vessel and washed with three 1-mL portions of DMF. This was then shaken with approximately 1.0 mL of approximately 177 mM solution *N*-tritylglycine 4-nitrophenylcarbonic anhydride solution (0.177 mmol) with approximately 531 mM DMAP (0.531 mmol) for 2 h. This was then filtered and washed with six 2-mL portions of DMF and six 2-mL portions of DCM. The trityl group was then removed by vortexing a solution of 5% TFA/5% TIS in DCM (4 x 1

mL) for 1 min each. The resin was then washed with six 1-mL portions of DCM, six 1-mL portions of DMF, 1 mL of 2 M DIEA in NMP, and three 1-mL portions of DMF to afford a tan resin (the resulting resin showed a positive ninhydrin test). The resin was then shaken with a solution of 64.0 mg *N*-trityl aminoethoxyacetic acid (Trt-AEA-OH) (0.177 mmol) dissolved in a solution of 393 μ L of a 0.45 M HBTU/HOBt, 393 μ L of DMF, and 88.5 μ L of 2 M DIEA in NMP for 1 h. The resin was washed with six 1-ml portions of DMF and six 1-mL portions of DCM to afford a tan resin (the resulting resin showed a negative ninhydrin test). The trityl group was then removed by vortexing a solution of 5% TFA/5% triisopropylsilane (TIS) in DCM (4 x 1 mL) for 1 min each, then washed with six 1-mL portions of DCM, six 1-mL portions of DMF, 1 mL of 2 M DIEA in NMP, and three 1-mL portions of DMF to afford a tan resin (the resulting resin showed a positive ninhydrin test). The tan resin was then shaken with a solution of 50.3 mg fluorescein isothiocyanate isomer I (FITC) (0.116 mmol) and 11 μ L TEA (0.079 mmol) for 10 min. The resin was filtered and washed with six 1-mL portions of DMF and six 1-mL portions of DCM to afford a tan resin (the resulting resin showed a negative ninhydrin test). The resin was then treated with two 1-mL portions of cleavage cocktail solution (10 mL TFA, 0.5 mL water and 0.5 mL TIS) for 1 h each. The combined cleavage filtrates were concentrated by rotary evaporation to 0.5 mL and crude product was then isolated by precipitation with 13 mL dry-ice cold Et₂O followed by centrifugation. After decanting the supernatant, the resulting white solid was re-suspended in 13 mL dry-ice cold ether, centrifuged, and decanted two times. This was then dissolved in 2 mL of 0.045% TFA in CH₃CN and 3 mL of 0.045% TFA in water and purified by preparative reverse-phase HPLC to afford 6.4 mg fluorescein-thiourea-AEA-Gly-OPh-CO-F/YEE-NH₂ as a yellow-orange solid (0.005 mmol, 13%). Anal. HPLC indicated product to be >95% pure with R_t = 58.14 min. ESI-MS *m/z* for C₆₈H₇₀N₉O₂₀S (MH⁺), calcd 1364.4, found 1366.3, MH²⁺ 683.9.

Example 4a: HSA Screening of Library at level of 81 Compounds Per Well with a 1 minute quenching time

The S-linked library described in Example 1 was constructed and screened against HSA using the general experimental procedures described in the "General Library Screening" Section above. Using a 1 minute quenching time, the screening procedures were first carried out at the level of 81 compounds per well with 81 distinct wells. At this level of screening, (see Fig. 4) each well contains a mixture of compounds of the formula Biotin-S-Ph-C(O)-O₁-O₂-X₁-X₂-B-NH₂, with X₁ and X₂ fixed for each well and each well containing a mixture of the 81 combinations of possible O₁ and O₂ amino acids. B is fixed as glutamic acid. The amino acid residue at position O₂ is an L-amino acid; the amino acid residues at all other positions are D-amino acids. Quenching time was fixed at 1 minute.

A rapid quench (1 minute) destroys the slow unreacted library members, thus limiting nonspecific bonding due to reaction of the library members with other nucleophiles that compete with the same reactive functional group. Fast quenching is advantageous since it facilitates identification of a lead affinity group in spite of the limited amount of biotin added. ELISA assays were used and the optical density results shown in Table II were recorded. Table II shows sort values calculated as $(\Delta O.D.-2xS.D.)/(background\ O.D.)$ and represented in Figure 4.

TABLE II

l-amino acid at position O ₁	d-amino acid at position O ₂								
	Glu	Gln	Arg	Met	Ser	Tyr	Leu	Phe	Trp
Glu	1.3	0.8	1.2	0.9	1.0	1.3	0.4	1.1	1.4
Gln	2.0	0.9	1.4	1.2	1.4	1.3	0.7	1.2	1.1
Arg	1.0	0.6	2.2	1.0	1.0	1.5	1.1	1.2	1.3
Met	1.0	1.4	1.3	1.3	1.2	1.3	1.0	1.3	1.2
Ser	0.8	1.0	1.0	0.8	1.2	1.3	1.3	1.5	0.6
Tyr	1.3	1.2	1.4	1.1	1.0	0.8	1.7	1.4	1.5
Leu	1.2	1.0	1.2	1.3	1.4	0.3	1.1	1.4	1.4
Phe	1.4	0.8	1.4	1.4	1.2	0.7	3.5	1.2	1.5

	d-amino acid at position O ₂								
l-amino acid at position O ₁	Glu	Gln	Arg	Met	Ser	Tyr	Leu	Phe	Trp
Trp	1.2	1.4	1.3	1.1	1.5	1.0	0.7	1.5	1.5

From these results, it appears that molecules of the formula Biotin-S-Ph-C(O)-F-l-X₁-X₂-E-NH₂ show the highest measured optical density. The optical density (OD) is approximately proportional to the amount of biotin added at a site on a given target. An elevated OD can thus be explained as an elevated amount of biotinylation for a given well. The driving force behind the increased rate of biotinylation is explained in terms of the enhanced specificity brought by some of the most efficient affinity groups. As a result, an elevated OD for a given well may be the result of an enhanced specificity of addition for some of the members in that well. Using a one minute quench screening, biotin-S-Ph-C(O)-F-l-X₁-X₂-E-NH₂ shows high specificity for HSA based on optical density reading.

Example 4b: HSA Screening of Library at level of 81 Compounds Per Well with a 15 minute quenching time

The S-linked library described in Example 1 was constructed and screened against HSA using the general experimental procedures described in the "General Library Screening" section above. Using a 15 minute quenching time, the screening procedures were first carried out at the level of 81 compounds per well with 81 distinct wells. At this level of screening, (see Fig. 5) each well contains a mixture of compounds of the formula biotin-S-Ph-C(O)-O₁-O₂-X₁-X₂-B-NH₂, with X₁ and X₂ fixed for each well and each well containing a mixture of the 81 combinations of possible O₁ and O₂ amino acids. B is fixed as glutamic acid. The amino acid residue at position O₂ is an L-amino acid; the amino acid residues at all other positions are D-amino acids. Table III shows sort values calculated as (Δ O.D.-2xS.D.)/(background O.D.), and represented in Figure 5.

Table III

l-amino acid at position O ₁	d-amino acid at position O ₂								
	Glu	Gln	Arg	Met	Ser	Tyr	Leu	Phe	Trp
Glu	3.3	3.6	3.6	1.2	2.3	3.6	3.2	6.1	11.3
Gln	5.6	4.6	3.0	2.1	2.1	3.7	5.8	4.2	4.0
Arg	3.5	3.2	9.4	2.3	3.0	3.9	3.9	3.3	3.4
Met	2.8	3.5	4.3	2.3	4.1	3.2	4.1	3.5	3.4
Ser	3.6	4.0	2.9	2.3	3.7	2.7	4.0	4.3	5.3
Tyr	3.9	3.5	2.8	2.6	5.4	6.3	4.9	5.8	4.9
Leu	3.9	3.1	3.2	2.6	4.5	3.3	2.4	4.2	4.6
Phe	4.0	3.7	3.1	2.8	4.3	6.0	4.4	4.1	6.1
Trp	9.8	5.1	3.1	3.2	8.8	9.0	8.2	5.1	10.9

Using a 15 minute quenching time, biotin-S-Ph-C(O)-W-W-X₁-X₂-E-NH₂ shows high specificity for HSA based on the readout of the optical density measured for each well.

Example 5: HSA Screening of Library at level of 9 Compounds Per Well

Each particular set of candidate affinity groups, once identified, must be rescreened or deconvoluted. ELISA assays were carried out at the level of 9 compounds per well and 9 wells where the compounds have the formula biotin-S-Ph-C(O)-F-I-X₁-X₂-E-NH₂ with X₁ fixed for each well and each well containing the 9 possible X₂ amino acid residues. Construction of these compounds per well libraries is described below.

Figures 6a and 6b show optical density measurements from screening of the 9 wells. These results show that molecules of the formula Biotin-S-Ph-C(O)-F-I-Y-X₂-E-NH₂ show enhanced affinity for HSA.

Example 6: Biological Methods and Materials

Fraction V HSA (Calbiochem) was suspended in PBS (Sigma) at 15 or 600 μM and stored at -20°C before use. Human plasma was obtained from Calbiochem, human serum from Sigma, and pig, dog, and human whole blood were obtained from healthy donors at Notre Dame Hospital in Montréal. The plasma was extracted by centrifugation of whole blood for 4 min at 500x g. D-biotin (Sigma) and NHS-LC-biotin (Pierce) were dissolved in DMSO (Sigma) at the required stock concentrations. Biotin-OPh-CO-F/YEE-NH₂, HO-Ph-CO-F/YEE-NH₂, biotin-OPh-CO-NH₂ were dissolved in DMSO at the required stock concentrations.

Biotinylation of Fraction V human serum albumin, human serum and whole blood

In order to determine the specificity of F/YEE, either 100 or 600 μM of biotin-OPh-CO-F/YEE-NH₂ or biotin-OPh-CO-NH₂ was added to individual samples of whole blood, plasma or serum. The reaction samples were allowed to incubate for 1h at RT or 37°C . For the whole blood sample, the plasma was extracted from whole blood at the end of reaction. Additional pig or dog plasma and fraction V HSA (600 μM final concentration) samples were prepared by mixing with 100 μM (final concentration) of biotin-OPh-CO-F/YEE-NH₂ or biotin-OPh-CO-NH₂ and allowed to incubate for 1h at RT or 37°C . These additional samples were diluted 1/60 in PBS and analyzed directly on SDS-PAGE, immunoblot, ELISA, or frozen at -20°C until use. As positive controls, 50 μM of NHS-LC-biotin (Pierce) and 100 μM of D-biotin were used. Protein assay was performed using BCA kit (Pierce).

Proteins were separated by SDS-PAGE under non-reducing conditions (Laemmli, 1970), transferred to 0.1 μm -pore nitrocellulose sheets (Schleicher and Schuell) and probed with peroxidase labeled streptavidin (Jackson Immuno Research). The biotinylated proteins were then revealed by an ECL detection kit (Pharmacia).

Competition ELISA test

A solution of 100 μL rabbit polyclonal anti-human serum albumin (Boehringer) diluted at 1/5000 in PBS was coated overnight at 4°C onto ELISA plates (Nunc). These plates were then saturated with 5% BSA (Sigma) in PBS for 2 h at RT.

For the competition test, varying concentrations of HO-Ph-CO- F/YEE -NH₂, 44 μ M biotin-OPh-CO-F/YEE-NH₂, and 15 μ M of fraction V HSA were incubated for 1 h at 37 °C. To assess the ability of biotin-OPh-CO-F/YEE-NH₂ to displace HO-Ph-CO-F/YEE -NH₂, varying concentrations of HO-Ph-CO- F/YEE -NH₂ were incubated with HSA for 1 h at 37 °C, then 44 μ M of biotin-OPh-CO-F/YEE-NH₂ was added and allowed to incubate at 37 °C for 1 h. The reaction mixtures were then centrifuged through 30 kDa Centricon tubes (Sarthorius) to a volume of 50 μ L, diluted with 500 μ L of PBS, then re-concentrated to 50 μ L. This process was then repeated and transferred to the ELISA plate previously coated with polyclonal anti-human serum albumin (procedure described above). These plates were then rinsed with PBS-Tween 20 (0.05%) three times, then with PBS. Peroxidase-labeled streptavidin (1:500, v/v, in PBS containing 0.05% BSA) was then added to the plates, allowed to incubate for 20 min at RT, rinsed with PBS-Tween 20 (0.05%) three times, and then with PBS. These rinsed plates were then treated with 100 μ L of 0.5 mg/mL solution of o-phenylene diethylamine (Sigma) in a 50 mM (pH 5) Na₂HPO₄/citrate buffer for 6 min at RT, then 50 μ L of 2N H₂SO₄ was added to quench the reaction. The plates were then read on a SpectraMax 250 at λ 490 nm.

Kinetic study by ELISA capture

A solution of 100 μ L of human plasma was treated with 100 μ M of NHS-LC-biotin, biotin-BMCC (Pierce), biotin-OPh-CO-F/YEE-NH₂ or biotin-OPh-CO-NH₂. The samples were then allowed to incubate at RT for 0, 5, 10, 15, 30 and 60 min, when 5 μ L of each sample was diluted with 295 μ L PBS and kept at -20 °C before use. The samples were then diluted to 2 μ g/mL using PBS and transferred to an ELISA plate previously coated with polyclonal anti-human serum albumin (procedure described above). The plates were then rinsed with PBS-Tween 20 (0.05%) three times, and then with PBS. Goat polyclonal anti-biotin (Pierce) (1:200, v/v, in PBS containing 0.05% BSA) was then added to the plates, allowed to incubate for 1 h at RT, rinsed with PBS-Tween 20 (0.05%) three times, and then with PBS. The plates were then treated with 100 μ L of peroxidase-conjugated rabbit anti-goat IgG (Jackson Immuno Research) diluted 1/100,000 with PBS for 20 min at RT. The plates were

then rinsed with PBS-Tween 20 (0.05%) three times, and then with PBS. The plates were then treated with a 0.5 mg/mL solution of o-phenylene diethylamine (Sigma) in a 50 mM (pH 5) Na_2HPO_4 /citrate buffer for 6 min at RT, then 50 μL of 2N H_2SO_4 was added to quench the reaction. The plates were then read on a SpectraMax 250 at λ 490 nm.

Example 7: Biological Results--Specificity of biotin-O-Ph-C(O)-FYEE-NH₂ is Species Dependent

Whole blood was incubated with biotin ester for 1 h at room temperature, then plasma was extracted by centrifugation. A 5 μg sample was separated by 8% SDS-PAGE and transferred to blot. The immunoblot was blocked with 5% skim milk (Nestlé) and then incubated with peroxidase labeled-streptavidin diluted at 1/5000 in PBS-BSA 0.5% for 20 min at RT. An ECL kit was used to detect peroxidase labeled-streptavidin on Hyperfilm ECL (Amersham), exposed for 1 min.

Example 8: Biological Results--Non-specificity of biotin-O-Ph-CO-NH₂: in absence of "FYEE" peptide, the biotinylated compound loses specificity

Figure 7 shows an immunoblot in which human serum and plasma samples in lanes 1, 2 and 3 were labeled with 100 μM biotin-O-Ph-CO-NH₂ and samples in lanes 4, 5 and 6 with 600 μM biotin-O-Ph-CO-NH₂ for 1 h at 37 °C. A 5 μg portion of each sample was separated by 8% SDS-PAGE and transferred onto blot. The immunoblot was blocked with 5% skim milk (Nestlé) and then incubated with peroxidase labeled-streptavidin diluted at 1/5000 in PBS-BSA 0.5% for 20 min at RT. An ECL kit was used to detect peroxidase labeled-streptavidin on Hyperfilm ECL (Amersham), exposed for 1 min. Lanes 1 and 4 were fresh human plasma, lanes 2 and 5 were commercial human serum and lanes 3 and 6 were commercial human plasma.

Example 9: Biological Results--Competition of biotin-O-Ph-CO-FYEE-NH₂ vs. HO-Ph-CO-FYEE-NH₂

Figure 8 plots optical density as a function of the concentration of HO-Ph-CO-FYEE-NH₂. In these experiments, solutions of 0 to 100 molar excess HO-Ph-CO-

F/YEE-NH₂ and 44 μM of biotin-Oph-CO-F/YEE-NH₂ were incubated with 15 μM of fraction V HSA for 1 h at 37 °C. The HSA was captured on an ELISA plate initially coated with polyclonal anti-HSA, treated with peroxidase labeled streptavidin and OD read at 490 nm using SpectraMax 250.

Example 10: Biological Results--Ability of biotin-Oph-CO-F/YEE-NH₂ to displace HO-Ph-CO-F/YEE-NH₂ on HSA

Figure 9 shows a plot of optical density as a function of the concentration of HO-Ph-CO-F/YEE-NH₂. In these experiments, solutions of 0 to 50 molar excess HO-Ph-CO-F/YEE-NH₂ and 15 μM fraction V HSA were incubated for 1 h at RT when 44 μM of biotin-Oph-CO-F/YEE-NH₂ was added and reaction incubated for 1 h at 37 °C. The HSA was captured on an ELISA plate initially coated with polyclonal anti-HSA, treated with peroxidase labeled streptavidin and OD read at 490 nm using SpectraMax 250.

Example 11: Biological Results--Rate of the reactivity of biotin-Oph-CO-F/YEE-NH₂ in plasma

Figure 9 shows the results of a kinetic study by ELISA capture experiment in which human plasma was treated with 100 μM biotin-Oph-CO-F/YEE-NH₂, biotin-Oph-CO-NH₂, NHS-LC-biotin or biotin-BMCC for 1 h at RT. At each time mentioned in the figure, 2 μg/mL of each sample was captured on an ELISA plate initially coated with polyclonal anti-HSA, treated with goat polyclonal anti-biotin, followed by peroxidase conjugated rabbit anti-goat IgG and OD read at 490 nm using SpectraMax 250.

Example 12: Biological Results--Kinetic Studies using HPLC

Rate determination was performed on a Rainin Dynamax HPLC system equipped with a 4.6 x 250 mm Microsorb 300Å C18 reverse phase column and UV detector at λ 214 and 245 nm running a gradient elution of 5-60% B (A: 0.045% TFA in H₂O and B: 0.045% TFA in CH₃CN) over 60 min at 0.5 mL/min. Each sample was prepared by mixing the appropriate amount of a stock solution of biotin-Oph-CO-

F/YEE-NH₂ or biotin-OPh-CO-NH₂ in either 600 μM fraction V HSA or commercial human plasma and injecting 20 μL of this solution onto the column using an autosampler at various time intervals. The chromatograms were each integrated using identical data parameters and resulting calculated areas under each peak converted to concentrations and plotted against time.

Figure 11 plots the rate of disappearance of biotin-OPh-CO-NH₂ vs. time and the rate of appearance of the leaving group, HO-Ph-CO-NH₂, vs. time.

Figure 12 plots the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds) as a result of the reaction of 100 μM biotin-OPh-CO-F/YEE-NH₂ in commercial human plasma. Due to overlapping peaks in the HPLC chromatogram, the rate of disappearance of biotin-OPh-CO-F/YEE-NH₂ cannot be determined.

Figure 13 shows a plot of the rate of hydrolysis of biotin-OPh-CO-F/YEE-NH₂ vs. time (seconds) and the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds).

Figure 14 shows a plot of the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds). Due to overlapping peaks in the HPLC chromatogram, the rate of disappearance of biotin-OPh-CO-F/YEE-NH₂ cannot be determined.

Figure 15 shows HPLC chromatographs of tryptic digest of HSA (top) and HSA:LC-biotin (bottom) where LC-biotin was introduced using LC-biotin-OPh-CO-F/YEE-NH₂. LC-biotin is biotin-NH-(CH₂)₅-C(O)-.

Discussion of Biological Results

Selectivity

Biotin-OPh-CO-F/YEE-NH₂ is selective to HSA. Immunoblots show the specificity of biotin-OPh-CO-F/YEE-NH₂ for human serum albumin (HSA) and not for pig or dog albumin in samples of whole blood.

Specificity

The specificity with which biotin-Oph-CO-F/YEE-NH₂ reacts with a specific lysine residue on HSA was determined by mass spectral analysis of a tryptic digest of LC-biotin conjugated to HSA by LC-biotin-Oph-CO-F/YEE-NH₂ (Figure 15). Using LC-biotin-Oph-CO-F/YEE-NH₂ instead of biotin-Oph-CO-F/YEE-NH₂ facilitated a larger mass separation in the mass spectrum and identification of HSA from HSA:LC-biotin. The differences in the two chromatograms are not immediately obvious, however; careful analysis of these chromatograms reveals two new peaks (Figure 15, arrows indicate the new peaks at 78 and 85 minutes). Mass spectral analysis of the new peak at 78 min showed a new peptide fragment with a mass of 2887.6 which corresponds to a peptide sequence of ⁵⁰¹EFNAETFNAETFTFHADIBTLSELYSKER⁵²¹ (where B = carboxymethyl cysteine) containing only one lysine residue where LC-biotin is attached, Lys₅₁₉. Mass spectral analysis of the new peak at 85 min showed a new peptide fragment with a mass of 5903.4, corresponding to a peptide sequence of: ⁴⁷⁶BBTESLVNRRPBFSALEVDETYVPK⁵⁰⁰EFNAETFNAETFTFHADIBTLSEKER⁵²¹ (where B = carboxymethyl cysteine), which contains two lysine residues (K₅₀₀ and K₅₁₉). This mass accounts only for the addition of one LC-biotin and since the fragment at 78 min contains only one Lys residue and LC-biotin is attached to it, and this peptide sequence contains the previous sequence, the only lysine residue in this sequence where biotin could be attached is Lys₅₁₉.

Because biotin-Oph-CO-F/YEE-NH₂ labels HSA selectively, is specific (Figure 15) and biotin-Oph-CO-NH₂ does not label selectively (Figure 7), it appears that biotin-Oph-CO-NH₂ will not label specifically and that the driving force to specificity is at least in part determined by the affinity portion of the molecule, the pentapeptide F/YEE-NH₂.

Reaction Kinetics

Prima facie evidence for the affinity of the F/YEE binding determinants for a specific site on the surface of HAS and its ability to direct pendant groups to such sites is supported by the results in Figures 8 and 9. The reaction of biotin-Oph-CO-F/YEE-NH₂ with HSA not only depends on concentration, but also on the amount of

leaving group (HO-Ph-CO-F/YEE-NH₂) present. Figures 8 and 9 suggest competition for the active site on HSA between biotin-Oph-CO-F/YEE-NH₂ and the leaving group HO-Ph-CO-F/YEE-NH₂, which competition could effect the rate of binding and subsequent bonding of biotin to HSA. As shown in Figure 8, direct competition of 0-100 molar excess of HO-Ph-CO-F/YEE-NH₂ and biotin-Oph-CO-F/YEE-NH₂ with 15 μ M HSA indicates that the excess HO-Ph-CO-F/YEE-NH₂ occupies a specific binding site on HSA, thus preventing the binding and subsequent bonding of biotin-Oph-CO-F/YEE-NH₂. As Figure 9 further illustrates, prior incubation of HO-Ph-CO-F/YEE-NH₂ with HSA prevents binding of biotin-Oph-CO-F/YEE-NH₂. This competition is observed only at the relatively higher concentrations of HO-Ph-CO-F/YEE-NH₂; between 1 to 5 molar excess of HO-Ph-CO-F/YEE-NH₂, competition has a very minor effect on the rate of reaction.

The influence of the affinity portion of the molecule (F/YEE-NH₂) on the rate of reaction is clearly seen by comparison of 100 μ M biotin-Oph-CO-NH₂ and 600 μ M HSA in PBS (Figure 11) with 100 μ M biotin-Oph-CO-F/YEE-NH₂ and 600 μ M HSA in PBS (Figure 14). The half-reaction for biotin-Oph-CO-NH₂ is about 330 min whereas that of biotin-Oph-CO-F/YEE-NH₂ is about 125 min. Under these reaction conditions, the rate of hydrolysis of the phenol ester is very slow (Figure 13) and has a half-life of about 7.2 days. Not only does the affinity portion of the molecule greatly influence the rate of reaction; the reaction medium or the form of albumin has a tremendous effect on the rate of reaction. The half-reaction of with 100 μ M biotin-Oph-CO-F/YEE-NH₂ in commercial human plasma is about 6 min. This dramatic change in rate is most likely due to conformational differences of HSA when in PBS and in plasma. This very rapid rate of reaction when in plasma is truly remarkable and is compelling evidence that an in vivo administration of a drug-Oph-CO-F/YEE-NH₂ molecule could be used as a possible therapeutic or diagnostic delivery agent.

Figures 10 and 12 show the kinetic of addition of biotin-Oph-CO-F/YEE-NH₂. Figure 10 shows the accelerated rate of biotin addition of biotin-Oph-CO-F/YEE-NH₂ when compared to biotin-Oph-CO-NH₂ (on the base line). As shown on Figure 12, after only five minutes, more than half of a 100 μ M biotin-Oph-CO-F/YEE-NH₂ has reacted with its protein target (in this case commercial human plasma).

We claim:

1. A compound according to the formula E-C_a-R-C_b-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C_a and C_b are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues -O₁-O₂-X₁-X₂-B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids.

2. A compound according to claim 1, wherein affinity group A comprises the sequence -O₁-O₂-X₁-X₂-B- wherein:

amino acid residue O₁ is selected from the group consisting of
phenylalanine, arginine, glutamine, tyrosine and tryptophan;
amino acid residue O₂ is selected from the group consisting of leucine,
arginine, glutamic acid, tryptophan and phenylalanine;
amino acid residue X₁ is selected from the group consisting of
phenylalanine, tryptophan, methionine and tyrosine;
amino acid residue X₂ is selected from the group consisting of serine,
arginine and glutamic acid; and
amino acid residue B is selected from the group consisting of serine,
arginine and glutamic acid.

3. A compound according to claim 2, wherein at least one of the amino acid residues is a D-amino acid and at least one is an L-amino acid.

4. A compound according to claim 2, wherein one of the five amino acid residues is an L amino acid residue and the other four amino acid residues are D amino acid residues.

5. A compound according to claim 3, wherein the L-amino acid residue is selected from the group consisting of the amino acid residue O₂, the amino acid residue X₁, and the amino acid residue X₂.

5 6. A compound according to claim 2, wherein one of the five amino acid residues is a D-amino acid residue and the other four amino acid residues are L-amino acid residues.

10 7. A compound according to claim 6, wherein the D-amino acid residue is selected from the group consisting of the amino acid residue O₂, amino acid residue X₁, and amino acid residue X₂.

15 8. A compound according to claim 7, wherein the D-amino acid residue is the amino acid residue O₂.

9. A compound according to claim 2, wherein O₁ is phenylalanine and O₂ is leucine.

10. A compound according to claim 2, wherein O₁ is arginine and O₂ is arginine.

20 11. A compound according to claim 2, wherein O₁ is glutamine and O₂ is glutamic acid.

12. A compound according to claim 2, wherein O₁ is glutamic acid and O₂ is tryptophan.

25 13. A compound according to claim 2, wherein O₁ is tryptophan and O₂ is tryptophan.

14. A compound according to claim 2, wherein O₁ is tryptophan and O₂ is glutamic acid.

30 15. A compound according to claim 2, wherein X₁ is tyrosine.

F/YEE-NH₂ or biotin-OPh-CO-NH₂ in either 600 μM fraction V HSA or commercial human plasma and injecting 20 μL of this solution onto the column using an autosampler at various time intervals. The chromatograms were each integrated using identical data parameters and resulting calculated areas under each peak converted to concentrations and plotted against time.

Figure 11 plots the rate of disappearance of biotin-OPh-CO-NH₂ vs. time and the rate of appearance of the leaving group, HO-Ph-CO-NH₂, vs. time.

Figure 12 plots the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds) as a result of the reaction of 100 μM biotin-OPh-CO-F/YEE-NH₂ in commercial human plasma. Due to overlapping peaks in the HPLC chromatogram, the rate of disappearance of biotin-OPh-CO-F/YEE-NH₂ cannot be determined.

Figure 13 shows a plot of the rate of hydrolysis of biotin-OPh-CO-F/YEE-NH₂ vs. time (seconds) and the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds).

Figure 14 shows a plot of the rate of appearance of the leaving group, HO-Ph-CO-F/YEE-NH₂, vs. time (seconds). Due to overlapping peaks in the HPLC chromatogram, the rate of disappearance of biotin-OPh-CO-F/YEE-NH₂ cannot be determined.

Figures 15A and 15B show HPLC chromatographs of tryptic digest of HSA (top) and HSA:LC-biotin (bottom) where LC-biotin was introduced using LC-biotin-OPh-CO-F/YEE-NH₂. LC-biotin is biotin-NH-(CH₂)₅-C(O)-.

Discussion of Biological Results

Selectivity

Biotin-OPh-CO-F/YEE-NH₂ is selective to HSA. Immunoblots show the specificity of biotin-OPh-CO-F/YEE-NH₂ for human serum albumin (HSA) and not for pig or dog albumin in samples of whole blood.

Specificity

The specificity with which biotin-OPh-CO-F/YEE-NH₂ reacts with a specific lysine residue on HSA was determined by mass spectral analysis of a tryptic digest of LC-biotin conjugated to HSA by LC-biotin-OPh-CO-F/YEE-NH₂ (Figures 15A and 15B). Using LC-biotin-OPh-CO-F/YEE-NH₂ instead of biotin-OPh-CO-F/YEE-NH₂ facilitated a larger mass separation in the mass spectrum and identification of HSA from HSA:LC-biotin. The differences in the two chromatograms are not immediately obvious, however; careful analysis of these chromatograms reveals two new peaks (Figures 15A and 15B, arrows indicate the new peaks at 78 and 85 minutes). Mass spectral analysis of the new peak at 78 min showed a new peptide fragment with a mass of 2887.6 which corresponds to a peptide sequence of ⁵⁰¹EFNAETFNAETFTHADIBTLSELYSKER⁵²¹ (where B = carboxymethyl cysteine) containing only one lysine residue where LC-biotin is attached, Lys₅₁₉. Mass spectral analysis of the new peak at 85 min showed a new peptide fragment with a mass of 5903.4, corresponding to a peptide sequence of: ⁴⁷⁶BBTESLVNRRPBFSALEVDETYVPK⁵⁰⁰EFNAETFNAETFTHADIBTLSEKER⁵²¹ (where B = carboxymethyl cysteine), which contains two lysine residues (K₅₀₀ and K₅₁₉). This mass accounts only for the addition of one LC-biotin and since the fragment at 78 min contains only one Lys residue and LC-biotin is attached to it, and this peptide sequence contains the previous sequence, the only lysine residue in this sequence where biotin could be attached is Lys₅₁₉.

Because biotin-OPh-CO-F/YEE-NH₂ labels HSA selectively, is specific (Figures 15A and 15B) and biotin-OPh-CO-NH₂ does not label selectively (Figure 7), it appears that biotin-OPh-CO-NH₂ will not label specifically and that the driving force to specificity is at least in part determined by the affinity portion of the molecule, the pentapeptide F/YEE-NH₂.

Reaction Kinetics

Prima facie evidence for the affinity of the F/YEE binding determinants for a specific site on the surface of HAS and its ability to direct pendant groups to such sites is supported by the results in Figures 8 and 9. The reaction of biotin-OPh-CO-F/YEE-NH₂ with HSA not only depends on concentration, but also on the amount of

Drugs which have been approved for use with humans have already been shown to be generally safe at the prescribed dosage and effective. Therefore, there are substantial advantages in being able to modify these drugs, where their safety and efficacy are not unduly altered. In this way, the economies of dealing with known entities can be achieved, while at the same time increasing the available therapeutic opportunities.

BRIEF SUMMARY OF THE INVENTION

The present invention addresses these and other problems of the prior art by providing compounds having the formula $E-C_a-R-C_b-A$. In this formula, E contains an active diagnostic moiety or pharmacophore and suitable connectors, R is a potentially reactive functional group contained within the entity and is capable of transferring an active diagnostic moiety or pharmacophore. C_a and C_b are connector groups between E and R and between R and A, respectively. A is any molecule or part of a molecule that possess specific binding determinants for a target molecule, such as proteins including human serum albumin. (These components of compounds according to the present invention are defined more fully below.) In some compounds according to the invention, affinity group A comprises a sequence of amino acid residues $-O_1-O_2-X_1-X_2-B$ in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. A particularly preferred sequence is F/YEE. Preferred compounds according to the invention include biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-OPh-C(O)-F/YEE-NH₂, LC-biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-Gly-OPh-C(O)-F/YEE-NH₂, fluorescein-Gly-OPh-F/YEE-NH₂, LC-biotin-OPh-C(O)-F/YEE-NH₂, argatroban-AEA₃-βAla-Gly-OPh-C(O)-F/YEE-NH₂ and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-F/YEE-NH₂, where LC is (for "long chain") has the formula $-NH-(CH_2)_n-C(O)-$, where n is an integer between 1 and 25. These compounds can bind to specific proteins in vivo and enhance the half lives of diagnostic and therapeutic agents as well as control side effects.

The present invention is also directed to methods for screening for the affinity of a compound for active sites on a target molecule. In methods according to the invention, the target molecule is immobilized on a test substrate and then incubated

with the compound under conditions that support interaction (i.e., noncovalent binding) between the compound and the active sites on the target molecule. Then, the interaction between the active sites and the compound is quenched. Thereafter, an assay can be performed to detect the activity of the target molecule.

This invention could be seen as a replacement for some antibody uses, particularly in the field of in vitro diagnostic or in vivo therapy. The present invention is an improvement on US Patent 5 612 034 (Pouletty, et al.) teaching the art of labeling protein in vivo in a nonspecific manner since the present invention extends the life of the drug and controls its distribution, thereby limiting its side effects.

BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be better understood by reference to the figures, in which:

Figure 1 shows the structural formula of the most preferred affinity group of the invention, -F/YEE.

Figure 2 shows a reaction scheme for the use of a preferred embodiment of the invention for covalently attaching biotin to HSA.

Figure 3 shows a schematic illustration of the construction of an affinity labeling library of the present invention.

Figure 4 shows optical density measurement for the screening of a library according to the present invention at the level of 81 compounds per well with a 1 minute quenching time

Figure 5 shows optical density measurement for the screening of a library according to the present invention at the level of 81 compounds per well with a 15 minutes quenching.

Figures 6a and 6b show optical density measurements for the screening of a library according to the present invention at the level of 9 compounds per well.

Figure 7 shows an immunoblot in which human serum and plasma samples were labeled with two different concentrations of biotin-OPh-CO- NH₂ to assess compound lack of specificity in the absence of F/YEE peptide.

Figure 8 shows a plot of optical density as a function of HO-Ph-CO- F/YEE- NH₂ concentration in an experiment to investigate competitive binding to HSA.

Figure 9 shows a plot of optical density as a function of HO-Ph-CO- F/YEE -NH₂ concentration in an experiment to investigate competitive binding to HSA as compared to biotin-Oph-CO-F/YEE- NH₂.

Figure 10 shows a plot of optical density as a function of time for a kinetic study by ELISA capture in which human plasma was treated with biotin-Oph-CO-F/YEE- NH₂, biotin-Oph-CO- NH₂, NHS-LC-biotin or biotin-BMCC (BMCC is 1-biotinamido-4-[4'-(maleimidomethyl)cyclohexanecarboxamido]butane).

Figure 11 shows a graph showing the rate of disappearance of biotin-Oph-CO-NH₂ and appearance of HO-Ph-CO- NH₂ as a result of reaction of HSA with biotin-Oph-CO- NH₂.

Figure 12 shows a plot of the concentration of HO-Ph-CO-F/YEE -NH₂ resulting from the reaction of biotin-Oph-F/YEE-NH₂ in commercial human plasma as a function of time.

Figure 13 shows a plot of the concentration of HO-Ph-CO- F/YEE -NH₂ and biotin-Oph-CO-F/YEE -NH₂ as a function of time during hydrolysis of biotin-Oph-CO-F/YEE- NH₂ in PBS (pH 7.4, RT).

Figure 14 shows a plot of the concentration of HO-Ph-CO- F/YEE -NH₂ as a function of time during reaction of biotin-Oph-CO- F/YEE- NH₂ with HSA in PBS (pH 7.4, RT).

Figures 15A and 15B show HPLC chromatographs of tryptic digest of HSA (top) and HSA:LC-biotin (bottom).

Figure 16 is a reaction scheme setting forth the procedure for the synthesis of biotin-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 17 is a reaction scheme setting forth the procedure for the synthesis of biotin-Gly-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 18 is a reaction scheme setting forth the procedure for the synthesis of LC-biotin-Oph-CO-F/YEE-NH₂ according to the invention.

Figure 19 is a reaction scheme setting forth the procedure for the synthesis of argatroban-AEA₃-βAla-Gly-Oph-CO-F/YEE-NH₂ •2 TFA according to the invention.

Figure 20 is a reaction scheme setting forth the procedure for the synthesis of Fluorescein-thiourea-AEA-Gly-Oph-CO-F/YEE-NH₂ according to the invention.

16. A compound according to claim 2, wherein X_2 is glutamic acid.

17. A compound according to claim 2, wherein B is glutamic acid.

5

18. A compound according to claim 2, wherein O_1 is phenylalanine, O_2 is D-leucine, X_1 is tyrosine, X_2 is glutamic acid, and B is glutamic acid.

10

19. A compound according to claim 2, wherein the amino acid residue B is a C-terminal amino acid residue.

20. A compound according to claim 19, wherein the affinity group comprises the amino acid sequence $-O_1-O_2-X_1-X_2-B-NH_2$.

15

21. A compound according to claim 2, wherein the compound further includes a reactive group attached to the affinity group, and wherein the reactive group includes a functional group selected from the group consisting of carboxy, phosphoryl, alkyl esters, thioesters, phosphoesters, ortho esters, imidates, mixed anhydrides and disulphides.

20

22. A compound according to claim 21, wherein the reactive group is bonded directly to the O_1 amino acid residue in the affinity group.

25

23. A compound according to claim 22, wherein the reactive group is bonded to the O_1 amino acid residue by an amide linkage.

30

24. A compound according to claim 21, wherein the reactive group has the formula $-X-R_1-C(O)-$, where $C(O)$ is an alpha carboxyl, R_1 includes a substituted or unsubstituted aromatic group and X is selected from the group consisting of S, O and N.

25. A compound according to claim 24, wherein X is bonded directly to an aromatic carbon atom in R₁.

26. A compound according to claim 24, wherein R₁ is unsubstituted phenyl.

5

27. A compound according to claim 26, wherein the -X- and -C(O)- substituents are bonded to the unsubstituted phenyl in a para configuration.

10

28. A compound according to claim 24, wherein R₁ is phenyl substituted with one or more groups selected from the group consisting of a halogen, NO₂, SO₂NR₂, SO₃R, SO₂NH₂, SO₂NHF, NR₃⁺, CF₃, CCl₃, CBr₃, C≡N, SO₃H, CO₂H, CO₂R, CHO, CORNH₂, NHR, NR₂, OH, NHCOCH₃, NHCOR, OCH₃, OR, CH₃, CH₂CH₃ and RC₆H₅.

15

29. A compound according to claim 24, wherein the reactive moiety is bonded directly to the O₁ residue via the carboxyl carbon.

20

30. A compound according to claim 21, further comprising a first connecting group connecting the reactive group and the affinity group.

31. A compound according to claim 30, wherein the first connecting group is bonded to the reactive group via an ester, thioester, amide, sulfonate ester or sulfonamide linkage.

25

32. A compound according to claim 30, wherein the first connecting group is bonded to the O₁ amino acid residue in the affinity group via an ester, thioester, amide, sulfonamide, urea, thiourea or carbamate linkage.

30

33. A compound according to claim 30, wherein the first connecting group includes a backbone chain of between about 1 and about 25 atoms.

34. A compound according to claim 33, wherein the first connecting group includes a backbone chain of between about 2 and about 16 carbon atoms.

5 35. A compound according to claim 30, wherein the first connecting group includes an unsaturated carbon atom backbone chain of between about 1 and about 25 atoms.

36. A compound according to claim 21, further including an entity bonded to the reactive group.

10 37. A compound according to claim 36, wherein the entity is a therapeutic or diagnostic agent.

15 38. A compound according to claim 36, wherein the entity is bonded directly to the reactive group by a linkage selected from the group consisting of an amide linkage, an ester linkage, a thioester linkage and a sulfonate ester linkage.

39. A compound according to claim 38, wherein the entity is bonded to the reactive group by an ester or thioester linkage.

20 40. A compound according to claim 36, further comprising a second connecting group connecting the entity to the reactive group.

25 41. A compound according to claim 40, wherein the second connecting group is bonded to the entity by an ester, thioester, amide, sulfonate ester or sulfonamide linkage.

42. A compound according to claim 40, wherein the second connecting group is bonded to the reactive group by an ester, thioester, amide or sulfonate ester linkage.

30 43. A compound according to claim 40, wherein the second connecting group includes a backbone chain of between about 1 and about 25 atoms.

44. A compound according to claim 43, wherein the second connecting group includes a backbone chain of between about 2 and about 16 carbon atoms.

5 45. A compound according to claim 40, wherein the second connecting group includes an unsaturated carbon atom backbone chain of between about 1 and about 25 atoms.

46. A compound according to claim 36, wherein the entity comprises a biotinyl group.

10

47. A compound according to claim 46, wherein the biotinyl group is bonded directly to the reactive group by an ester, thioester or amide linkage.

15

48. A compound according to claim 46, wherein the reactive group has the formula -X-Ph-C(O)-, and where X is oxygen, sulfur or nitrogen.

49. A compound according to claim 48, wherein the -X- and -C(O)- substituents on the Ph group are bonded in a para configuration.

20

50. A compound according to claim 47, further comprising a second connecting group connecting the biotin group to the reactive group.

51. A compound according to claim 50, wherein the second connecting group is bonded to the biotin group by an amide linkage.

25

52. A compound according to claim 50, wherein the second connecting group is -NH-(CH₂)_n-C(O)-, where n is an integer between 1 and 25.

30

53. A compound according to claim 52, wherein the second connecting group is -NH-(CH₂)₅-C(O)-.

54. A compound according to claim 52, wherein the second connecting group is $-\text{NH}-\text{CH}_2-\text{C}(\text{O})-$.
- 5 55. A compound selected from the group consisting of biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-OPh-C(O)-F/YEE-NH₂, LC-biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-Gly-OPh-C(O)-F/YEE-NH₂, fluorescein-Gly-OPh-F/YEE-NH₂, LC-biotin-OPh-C(O)-F/YEE-NH₂, argatroban-AEA₃-βAla-Gly-OPh-C(O)-F/YEE-NH₂, and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-F/YEE-NH₂.
- 10 56. A method for screening for the affinity of a compound for human serum albumin, comprising the steps of:
- a) immobilizing the albumin on a test substrate;
 - 15 b) incubating the compound with the albumin under conditions that support covalent interaction between the compound and the albumin;
 - c) quenching the interaction between the albumin and the compound; and
 - 20 d) assaying for activity of the albumin, wherein the compound is of the formula $\text{E}-\text{C}_a-\text{R}-\text{C}_b-\text{A}$, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C_a and C_b are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for albumin, wherein affinity group A comprises a sequence of amino acid residues in which the amino acid residues are independently selected
 - 25 from the group of all twenty naturally occurring amino acids.
57. A method according to claim 56 wherein the entity E is selected from the group consisting of biotin, fluorescein and argatroban.

54. A compound according to claim 52, wherein the second connecting group is $-NH-CH_2-C(O)-$.

55. A compound selected from the group consisting of biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-OPh-C(O)-F/YEE-NH₂, LC-biotin-S-Ph-C(O)-F/YEE-NH₂, biotin-Gly-OPh-C(O)-F/YEE-NH₂, fluorescein-Gly-OPh-F/YEE-NH₂, LC-biotin-OPh-C(O)-F/YEE-NH₂, argatroban-AEA₃-βAla-Gly-OPh-C(O)-F/YEE-NH₂, and fluorescein-thiourea-AEA₃-Gly-OPh-C(O)-F/YEE-NH₂.

56. A method for screening for the affinity of a compound for human serum albumin, comprising the steps of:

a) immobilizing the albumin on a test substrate;

b) incubating the compound with the albumin under conditions that support covalent interaction between the compound and the albumin;

c) quenching the interaction between the albumin and the compound; and


d) assaying for activity of the albumin, wherein the compound is of the formula E-C_a-R-C_b-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C_a and C_b are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for albumin, wherein affinity group A comprises a sequence of amino acid residues in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids.

57.A method according to claim 56 wherein the entity E is selected from the group consisting of biotin, fluorescein and argatroban.


ABSTRACT OF THE DISCLOSURE

Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-C_a-R-C_b-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C_a and C_b are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues -O₁-O₂-X₁-X₂-B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling *in vivo*, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.

1/20

**FIG. 1**

2/20





3D bar chart showing the difference in "EASY" SORT VALUE MINUS X for HSA/ALL5/1 min. The chart compares L-AMINO ACID @ POSITION 5 (X-axis) and D-AMINO ACID @ POSITION 4 (Z-axis) for various amino acids (Y-axis). The Y-axis ranges from 0.0 to 2.5. The X-axis lists amino acids: GLU, GLN, ARG, MET, SER, TYR, LEU, PHE, TRP. The Z-axis lists amino acids: GLU, GLN, ARG, MET, SER, TYR, LEU, PHE, TRP. The chart shows that for most amino acids, the L-AMINO ACID @ POSITION 5 value is higher than the D-AMINO ACID @ POSITION 4 value, with the most significant difference for TRP.

FIG. 4

5/20





FIG. 5


6/20



REACTION OF HSA WITH BIOTIN-S-(PHENYL)CONH-F-L-O-X-NH₂;
QUENCH TIME = 5 sec.

FIG. 6A

7/20



REACTION OF HSA WITH BIOTIN-S-(PHENYL)*p* CONH-W-E-O-X-NH₂;
QUENCH TIME = 5 SEC.

FIG. 6B

8/20






FIG. 7

9/20




COMPETITION OF BIOTIN-OPh-CO-F/YEE-NH₂ (44 μM)
vs. HO-Ph-CO-F/YEE-NH₂

FIG. 8



"COMPETITION" TEST BETWEEN BIOTIN-OPh-F/YEE-NH₂
(44 μM) AND HO-Ph-CO-F/YEE-NH₂


FIG. 9



KINETIC STUDY BY ELISA CAPTURE

FIG. 10


11/20



RATE OF REACTION OF 600 μM HSA WITH 100 μM BIOTIN-OPh-CONH₂ IN pH 7.4 PBS AT RT

FIG. 11


12/20



RATE OF REACTION OF 100 μM BIOTIN-OPh-CO-F/YEE-NH₂
IN COMMERCIAL HUMAN PLASMA

FIG. 12


13/20



RATE OF HYDROLYSIS OF 100 μM BIOTIN-OPh-CO-F/YEE-NH₂
IN pH 7.4 PBS AT RT

FIG. 13

14/20




RATE OF REACTION OF 100 μM BIOTIN-OPh-CO-F/YEE-NH₂
WITH 600 μM HSA AT RT


FIG. 14

15/20

"DEVICE A" FROM HSACONTROL(BOPhF/YEE)RCM-TD

**FIG. 15A**


"DEVICE A" FROM HSA-BIO(OPhF/YEE)-RCM-TD

**FIG. 15B**



16/20

DP=DEPROTECT WITH 20% PIPERIDINE

1. DP, then Fmoc-Glu(OtBu)-OH
2. DP, then Fmoc-Glu(OtBu)-OH
3. DP, then Fmoc-Tyr(tBu)-OH
4. DP, then Fmoc-D-Leu-OH
5. DP, then Fmoc-Phe-OH
6. DP, Fmoc-OPh-CO₂H, DP




Fmoc-RINK AMIDE MBHA RESIN



BIOTIN-OPh-CO-FYEE-NH₂


FIG. 16




 Fmoc-Rink AMIDE MBHA RESIN

1.	DP, then Fmoc-Glu(OtBu)-OH
2.	DP, then Fmoc-Glu(OtBu)-OH
3.	DP, then Fmoc-Tyr(tBu)-OH
4.	DP, then Fmoc-D-Leu-OH
5.	DP, then Fmoc-Phe-OH
6.	DP, Fmoc-OPh-CO ₂ H, DP

1. DP, then Fmoc-Glu(OtBu)-OH
2. DP, then Fmoc-Glu(OtBu)-OH
3. DP, then Fmoc-Tyr(tBu)-OH
4. DP, then Fmoc-D-Leu-OH
5. DP, then Fmoc-Phe-OH
6. DP, Fmoc-OPh-CO₂H, DP

BIOTIN-Gly-OPh-CO-F/YEE-NH₂

18/20






FIG. 19

SYNTHETIC SCHEMES

DP=DEPROTECT WITH 20% PIPERIDINE

1. DP, then Fmoc-Glu(OtBu)-OH
2. DP, then Fmoc-Glu(OtBu)-OH
3. DP, then Fmoc-Tyr(tBu)-OH
4. DP, then Fmoc-D-Leu-OH
5. DP, then Fmoc-Phe-OH
6. DP, Fmoc-OPh-CO₂H, DP






FIG. 20

FLUORESCIN-THIOUREA-AEA₃-Gly-OPh-CO-FYEE-NH₂

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

the specification of which (check one) is attached hereto or X was filed on 06 November 1998 as International Application No. PCT/US98/23705, and was amended on 16 March 1999 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed
Yes No

Number Country Day/Month/Year Filed

Number Country Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

60/064,705 07 November 1997
Application Number Filing Date

60/077,927 13 March 1998
Application Number Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number Filing Date Status: Patented, Pending, Abandoned

Application Number Filing Date Status: Patented, Pending, Abandoned

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:

Karl A. Limbach	18,689	Alfred A. EQUITZ	30,922	Kyla L. Harriel	41,816
George C. Limbach	19,305	Charles P. Sammut	28,901	Mayumi Maeda	40,075
John K. Uilkema	20,282	Mark C. Pickering	36,239	Kent J. Tobin	39,496
Neil A. Smith	25,441	Patricia Coleman James	37,146	Michael R. Ward	38,651
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Roger S. Sampson	44,314
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Tina Chen	44,606
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Charles L. Hamilton	42,624
Michael A. Stallman	29,444	Seong-Kun Oh*		Andrew V. Smith	43,132
Philip A. Girard	28,848	Cameron A. King	41,897	Eric N. Hoover	37,355
Michael J. Pollock	29,088			J. Thomas McCarthy	22,420
Stephen M. Everett	30,050			Joel G. Ackerman	24,307

* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.
 Attn: Michael R. Ward, Esq.
2001 Ferry Building
San Francisco, CA 94111
 Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor ALEXANDER KRANTZ

Inventor's signature Alexander Krantz

Residence 2713 Bay Area W,

Citizenship United States of America

Post Office Address Same

Date 8/11/00

Full name of second joint inventor, if any, WOLIN HUANG

Inventor's signature _____

Date _____

Residence 872 Arcturus Circle, Foster City, California 94404

Citizenship United States of America

Post Office Address 872 Arcturus Circle, Foster City, California 94404

Full name of third joint inventor, if any, ARTHUR M. HANEL

Inventor's signature _____

Date _____

Residence 195 Eureka Street, #5, San Francisco, California 94414

Citizenship United States of America

Post Office Address 195 Eureka Street, #5, San Francisco, California 94414

Full name of fourth joint inventor, if any, DARREN L. HOLMES

Inventor's signature _____

_____ Date

Residence 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Citizenship United States of America

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Full name of fifth joint inventor, if any, DOMINIQUE P. BRIDON

Inventor's signature _____

_____ Date

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:

Karl A. Limbach	18,689	Alfred A. Equitz	30,922	Kyla L. Harriel	41,816
George C. Limbach	19,305	Charles P. Sammut	28,901	Mayumi Maeda	40,075
John K. Uilkema	20,282	Mark C. Pickering	36,239	Kent J. Tobin	39,496
Neil A. Smith	25,441	Patricia Coleman James	37,155	Michael R. Ward	38,651
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Roger S. Sampson	44,314
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Tina Chen	44,606
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Charles L. Hamilton	42,624
Michael A. Stallman	29,444	Seong-Kun Oh*		Andrew V. Smith	43,132
Philip A. Girard	28,848	Cameron A. King	41,897	Eric N. Hoover	37,355
Michael J. Pollock	29,098			J. Thomas McCarthy	22,420
Stephen M. Everett	30,050			Joel G. Ackerman	24,307

* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.
Attn: Michael R. Ward, Esq.
2001 Ferry Building
San Francisco, CA 94111
Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor ALEXANDER KRANTZ

Inventor's signature _____
2713 Bay Avenue West, Tampa, Florida 33611 Date
Residence ~~847 North Humboldt Street, #310, San Mateo, California 94401~~
Citizenship United States of America
Post Office Address ~~847 North Humboldt Street, #310, San Mateo, California 94401~~
2713 Bay Avenue West, Tampa, Florida 33611

Full name of second joint inventor, if any, WOLIN HUANG

Inventor's signature Wolin Huang 4-28-00 Date
Residence 872 Arcturus Circle, Foster City, California 94404
Citizenship United States of America
Post Office Address 872 Arcturus Circle, Foster City, California 94404

Full name of third joint inventor, if any, ARTHUR M. HANEL

Inventor's signature _____ Date
Residence 195 Eureka Street, #5, San Francisco, California 94414
Citizenship United States of America
Post Office Address 195 Eureka Street, #5, San Francisco, California 94414

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:

Karl A. Limbach	18,689	Alfred A. Equitz	30,922	Kyla L. Harriel	41,816
George C. Limbach	19,305	Charles P. Sammut	28,901	Mayumi Maeda	40,075
John K. Uilkema	20,282	Mark C. Pickering	36,239	Kent J. Tobin	39,496
Neil A. Smith	25,441	Patricia Coleman James	37,155	Michael R. Ward	38,651
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Roger S. Sampson	44,314
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Tina Chen	44,606
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Charles L. Hamilton	42,624
Michael A. Stallman	29,444	Seong-Kun Oh*		Andrew V. Smith	43,132
Philip A. Girard	28,848	Cameron A. King	41,897	Eric N. Hoover	37,355
Michael J. Pollock	29,098			J. Thomas McCarthy	22,420
Stephen M. Everett	30,050			Joel G. Ackerman	24,307

* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.
Attn: Michael R. Ward, Esq.
2001 Ferry Building
San Francisco, CA 94111
Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor ALEXANDER KRANTZ

Inventor's signature _____
2713 Bay Avenue West, Tampa, Florida 33611 Date
Residence 847 North Humboldt Street, #310, San Mateo, California 94401
Citizenship United States of America
Post Office Address 847 North Humboldt Street, #310, San Mateo, California 94401
2713 Bay Avenue West, Tampa, Florida 33611

Full name of second joint inventor, if any, WOLIN HUANG

Inventor's signature _____ Date _____
Residence 872 Arcturus Circle, Foster City, California 94404
Citizenship United States of America
Post Office Address 872 Arcturus Circle, Foster City, California 94404

Full name of third joint inventor, if any, ARTHUR M. HANEL

Inventor's signature Arthur M. Hanel Date 4/14/00
Residence 195 Eureka Street, #5, San Francisco, California 94414
Citizenship United States of America
Post Office Address 195 Eureka Street, #5, San Francisco, California 94414

4-00
Full name of fourth joint inventor, if any, DARREN L. HOLMES

Inventor's signature Darren L. Holmes

Date

April 12, 2000

Residence 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Citizenship United States of America

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

5-00
Full name of fifth joint inventor, if any, DOMINIQUE P. BRIDON

Inventor's signature [Signature]

Date

April 13, 2000

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

the specification of which (check one) ☐ is attached hereto or ☒ was filed on 06 November 1998 as International Application No. PCT/US98/23705 and was preliminarily amended on 16 March 1999 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
			Yes	No
Number	Country	Day/Month/Year Filed		
Number	Country	Day/Month/Year Filed		

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

<u>60/064,705</u>	<u>07 November 1997</u>
Application Number	Filing Date
<u>60/077,927</u>	<u>13 March 1998</u>
Application Number	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: Patented, Pending, Abandoned
Application Number	Filing Date	Status: Patented, Pending, Abandoned

Atty Docket No. REDC-710 USA

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

the specification of which (check one) is attached hereto or X was filed on 06 November 1998 as International Application No. PCT/US98/23705 and was amended on 16 March 1999 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed
Yes No

Number	Country	Day/Month/Year Filed	_____	_____
--------	---------	----------------------	-------	-------

Number	Country	Day/Month/Year Filed	_____	_____
--------	---------	----------------------	-------	-------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

60/064,705	07 November 1997
Application Number	Filing Date

60/077,927	13 March 1998
Application Number	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: Patented, Pending, Abandoned
--------------------	-------------	--------------------------------------

Application Number	Filing Date	Status: Patented, Pending, Abandoned
--------------------	-------------	--------------------------------------

Full name of fourth joint inventor, if any, DARREN L. HOLMES

Inventor's signature _____ Date _____

Residence 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Citizenship United States of America

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Full name of fifth joint inventor, if any, DOMINIQUE P. BRIDON

Inventor's signature _____ Date _____

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN

the specification of which (check one) is attached hereto or X was filed on 06 November 1998 as International Application No. PCT/US98/23705 and was amended on 16 March 1999 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

Yes No

Number Country Day/Month/Year Filed

Number Country Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

60/064,705 07 November 1997

Application Number Filing Date

60/077,927 13 March 1998

Application Number Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number Filing Date Status: Patented, Pending, Abandoned

Application Number Filing Date Status: Patented, Pending, Abandoned

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:

Karl A. Limbach	18,689	Alfred A. Equitz	30,922	Kyla L. Harriel	41,816
George C. Limbach	19,305	Charles P. Sammut	28,901	Mayumi Maeda	40,075
John K. Ulkema	20,282	Mark C. Pickering	36,239	Kent J. Tobin	39,496
Neil A. Smith	25,441	Patricia Coleman James	37,155	Michael R. Ward	38,651
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Roger S. Sampson	44,314
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Tina Chen	44,606
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Charles L. Hamilton	42,624
Michael A. Stallman	29,444	Seong-Kun Oh*		Andrew V. Smith	43,132
Philip A. Girard	28,848	Cameron A. King	41,897	Eric N. Hoover	37,355
Michael J. Pollock	29,098			J. Thomas McCarthy	22,420
Stephen M. Everett	30,050			Joel G. Ackerman	24,307

* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.
 Attn: Michael R. Ward, Esq.
 2001 Ferry Building
 San Francisco, CA 94111
 Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor ALEXANDER KRANTZ

Inventor's signature _____

2713 Bay Avenue West, Tampa, Florida 33611 Date _____

Residence 847 North Humboldt Street, #310, San Mateo, California 94401

Citizenship United States of America

Post Office Address 847 North Humboldt Street, #310, San Mateo, California 94401

2713 Bay Avenue West, Tampa, Florida 33611

Full name of second joint inventor, if any, WOLIN HUANG

Inventor's signature _____

Date _____

Residence 872 Arcturus Circle, Foster City, California 94404

Citizenship United States of America

Post Office Address 872 Arcturus Circle, Foster City, California 94404

Full name of third joint inventor, if any, ARTHUR M. HANEL

Inventor's signature _____

Date _____

Residence 195 Eureka Street, #5, San Francisco, California 94414

Citizenship United States of America

Post Office Address 195 Eureka Street, #5, San Francisco, California 94414

Full name of fourth joint inventor, if any, DARREN L. HOLMES

Inventor's signature _____ Date _____

Residence 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Citizenship United States of America

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Full name of fifth joint inventor, if any, DOMINIQUE P. BRIDON

Inventor's signature _____ Date _____

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada